研究者データベース

研究者情報

マスター

アカウント(マスター)

  • 氏名

    津田 真寿美(ツダ マスミ), ツダ マスミ

所属(マスター)

  • 医学研究院 病理系部門 病理学分野

所属(マスター)

  • 医学研究院 病理系部門 病理学分野

独自項目

syllabus

  • 2020, ソフトマター科学概論, Soft Matter Science, 修士課程, 生命科学院, 生命融合科学、生命情報分子科学、生命物質科学、細胞機能科学、生命機能制御科学、ソフトマター科学、ソフトマター材料科学、ソフトマター生命分子科学、ソフトマター生体物理学、ソフトマター医科学、SDGs、
  • 2020, 生命融合科学概論, Transdisciplinary Life Science, 修士課程, 生命科学院, 生命融合科学、生命情報分子科学、生命物質科学、細胞機能科学、生命機能制御科学、ソフトマター科学、ソフトマター材料科学、ソフトマター生命分子科学、ソフトマター生体物理学、ソフトマター医科学、SDGs、
  • 2020, 基本医学総論, Basic Principles of Medicine, 修士課程, 医学院, 癌、癌幹細胞、癌遺伝子、シグナル伝達、癌治療、がんプロフェッショナル cancer, cancer stem cell, oncogene, signal transduction, cancer therapy, cancer professional
  • 2020, ソフトマター医工学特論, Soft Matter Medical Engineering, 修士課程, 生命科学院, 基礎医学、再生医学、バイオマテリアル、がん生物学
  • 2020, 医学総論, Principles of Medicine, 博士後期課程, 医学院, 癌、癌幹細胞、癌遺伝子、シグナル伝達、癌治療、がんプロフェッショナル
  • 2020, 病理学, Pathology, 学士課程, 医学部, 細胞と組織の基本的病的変化,疾患の種類と分類,疾患の病因と病態
  • 2020, 臨床病理学, Clinical Pathology, 学士課程, 医学部, 臨床診断、病理診断、診断の根拠と鑑別診断、治療の評価
  • 2020, 病理学演習, Pathology Case Studies, 学士課程, 医学部, 肉眼的病理診断、組織学的病理診断、最終診断、個体の総合的病態、ポスター/スライド発表
  • 2020, 病理学実習, Pathology Laboratory, 学士課程, 医学部, 組織病理、光学顕微鏡、バーチャルスライド、免疫染色、スケッチ

timetable

  • 学士課程, 医学部, 2020, 臨床病理学
  • 博士後期課程, 医学研究科, 2020, 医学総論

researchmap

プロフィール情報

所属

  • 北海道大学, 大学院医学研究院, 准教授
  • 北海道大学国際連携研究教育局

学位

  • 医学博士(北海道大学)

プロフィール情報

  • 津田, ツダ
  • 真寿美, マスミ
  • ID各種

    201301054796031119

対象リソース

所属

  • 北海道大学, 大学院医学研究院, 准教授
  • 北海道大学国際連携研究教育局

業績リスト

研究キーワード

  • ソフトマター   腫瘍血管新生   腫瘍微小環境   抗がん剤   腫瘍間質   骨転移   転写因子   診断技術   血管内皮細胞   治療標的分子   染色体転座   腫瘍環境   悪性腫瘍   軟部肉腫   治療   バイオイメージング   MET   EMT   EGFレセプター   口腔がん   血管新生   顎骨浸潤   リン酸化   

研究分野

  • ライフサイエンス / 腫瘍生物学
  • ライフサイエンス / 実験病理学
  • ライフサイエンス / 外科系歯学

経歴

  • 2017年06月 - 現在 北海道大学 医学(系)研究科(研究院) 准教授
  • 2014年10月 - 2017年05月 北海道大学 医学(系)研究科(研究院) 講師
  • 2007年04月 - 2014年09月 北海道大学 医学(系)研究科(研究院) 助教
  • 2006年04月 - 2007年03月 北海道大学 医学(系)研究科(研究院) 助手

論文

  • Shingo Semba, Nobuto Kitamura, Masumi Tsuda, Keiko Goto, Sadamu Kurono, Yoshihiro Ohmiya, Takayuki Kurokawa, Jian Ping Gong, Kazunori Yasuda, Shinya Tanaka
    Journal of Biomedical Materials Research Part A 2020年06月 [査読有り][通常論文]
  • Daiki Hashimoto, Shingo Semba, Masumi Tsuda, Takayuki Kurokawa, Nobuto Kitamura, Kazunori Yasuda, Jian Ping Gong, Shinya Tanaka
    Biochemical and Biophysical Research Communications 2020年05月 [査読有り][通常論文]
  • Toshihiro Kushibiki, Toru Nakamura, Masumi Tsuda, Takahiro Tsuchikawa, Koji Hontani, Kazuho Inoko, Mizuna Takahashi, Toshimichi Asano, Keisuke Okamura, Soichi Murakami, Yo Kurashima, Yuma Ebihara, Takehiro Noji, Yoshitsugu Nakanishi, Kimitaka Tanaka, Nako Maishi, Katsunori Sasaki, Woong-Ryeon Park, Toshiaki Shichinohe, Kyoko Hida, Shinya Tanaka, Satoshi Hirano
    Molecular cancer therapeutics 19 1 187 - 198 2020年01月 [査読有り][通常論文]
     
    Over the past 30 years, the therapeutic outcome for pancreatic ductal adenocarcinoma (PDAC) has remained stagnant due to the lack of effective treatments. We performed a genome-wide analysis to identify novel therapeutic targets for PDAC. Our analysis showed that Homo sapiens chromosome 16 open reading frame 74 (C16orf74) was upregulated in most patients with PDAC and associated with poor prognosis. Previously, we demonstrated that C16orf74 interacts with the catalytic subunit alpha of protein phosphatase 3 and plays an important role in PDAC invasion. However, the pathophysiologic function of C16orf74 is still unclear. In this study, through the analysis of C16orf74 interaction, we demonstrate a new strategy to inhibit the growth and invasion of PDAC. C16orf74 exists in the homodimer form under the cell membrane and binds integrin αVβ3 and is also involved in invasion by activating Rho family (Rac1) and MMP2. Considering that this dimeric form was found to be involved in the function of C16orf74, we designed an 11R-DB (dimer block) cell-permeable dominant-negative peptide that inhibits the dimer form of C16orf74. 11R-DB suppressed invasion and proliferation of PDAC cell lines by inhibiting phosphorylation of Akt and mTOR and also by inactivation of MMP2. 11R-DB also showed antitumor effects in an orthotopic xenograft model and peritoneal metastasis model. Thus, this study demonstrates that dimerized C16orf74, present in the cell membrane, is involved in pancreatic cancer invasion and proliferation. In addition, the C16orf74 dimer block cell-permeable peptide (11R-DB) has a potent therapeutic effect on PDAC in vitro and in vivo.
  • Kondo T, Fujioka M, Fujisawa S, Sato K, Tsuda M, Miyagishima T, Mori A, Iwasaki H, Kakinoki Y, Yamamoto S, Haseyama Y, Ando S, Shindo M, Ota S, Kurosawa M, Ohba Y, Teshima T, North Japan, Hematology Study Group, NJHSG
    Int J Hematol 110 4 482 - 489 2019年10月 [査読有り][通常論文]
  • Tanikawa S, Tanino M, Wang L, Ishikawa M, Miyazaki M, Tsuda M, Orba Y, Sawa H, Matoba K, Nakamura N, Nagashima K, Hall WW, Tanaka S
    Neuropathology : official journal of the Japanese Society of Neuropathology 39 5 374 - 377 2019年10月 [査読有り][通常論文]
  • Martin Frauenlob, Daniel R. King, Honglei Guo, Seiichiro Ishihara, Masumi Tsuda, Takayuki Kurokawa, Hisashi Haga, Shinya Tanaka, Jian Ping Gong
    Macromolecules 52 17 6704 - 6713 2019年08月 [査読有り][通常論文]
  • Yoshida K, Tsuda M, Matsumoto R, Semba S, Wang L, Sugino H, Tanino M, Kondo T, Tanabe K, Tanaka S
    Cancer science 110 7 2119 - 2132 2019年07月 [査読有り][通常論文]
     
    Locally advanced and metastatic invasive bladder cancer (BC) has a poor prognosis, and no advanced therapies beyond cisplatin-based combination chemotherapy have been developed. Therefore, it is an urgent issue to elucidate the underlying mechanisms of tumor progression and metastasis of invasive BC for the development of new therapeutic strategies. Here, we clarified a novel role of exosomes containing ErbB2 and CRK in a formation of premetastatic niches and subsequent metastases. CRK adaptors were overexpressed in invasive UM-UC-3 BC cells. In an orthotopic xenograft model, metastases to lung, liver, and bone of UM-UC-3 cells were completely abolished by CRK elimination. Mass spectrometry analysis identified that ErbB2 was contained in UM-UC-3-derived exosomes in a CRK-dependent manner; the exosomes significantly increased proliferation and invasion properties of low-grade 5637 BC cells and HUVECs through FAK and PI3K/AKT signaling pathways. In athymic mice educated with UM-UC-3-derived exosomes, i.v. implanted UM-UC-3 cells were trapped with surrounding PKH67-labeled exosomes in lung and led to development of lung metastasis with disordered vascular proliferation. In contrast, exosomes derived from CRK-depleted BC cells failed to induce these malignant features. Taken together, we showed that CRK adaptors elevated the expression of ErbB2/3 in BC cells, and these tyrosine kinase/adaptor units were transferred from host BC cells to metastatic recipient cells by exosomes, leading to vascular leakiness and proliferation and contributing to the formation of distant metastasis. Thus, CRK intervention with ErbB2/3 blockade might be a potent therapeutic strategy for patients with ErbB2 overexpressing advanced and metastatic BC.
  • 次世代シーケンサーを用いた肺原発多形癌の遺伝子変異解析
    長野 匡晃, 高阪 真路, 牛久 綾, 林 大久生, 田中 伸哉, 津田 真寿美, 篠原 敏也, 大森 優子, 菅谷 文子, 加藤 弘明, 成田 吉明, 高持 一矢, 鈴木 健司, 中島 淳, 間野 博行
    日本呼吸器外科学会雑誌 33 3 RO1 - 3 (NPO)日本呼吸器外科学会 2019年04月 [査読有り][通常論文]
  • Ishida Y, Tsuda M, Sawamura Y, Fujii K, Murai H, Horiuchi N, Orba Y, Sawa H, Hall WW, Nagashima K, Tanaka S
    Pathology international 68 12 694 - 699 2018年12月 [査読有り][通常論文]
  • Kondo T, Fujioka M, Tsuda M, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Nagashima T, Wakasa K, Fujimoto N, Yamamoto S, Yonezumi M, Saito S, Sato S, Ogawa K, Chou T, Watanabe R, Kato Y, Takahashi S, Okano Y, Yamamoto J, Ohta M, Iijima H, Oba K, Kishino S, Sakamoto J, Ishida Y, Ohba Y, Teshima T, Inter-Michinoku Dasatinib, Study Group, IMIDAS
    Cancer science 109 7 2256 - 2265 2018年07月 [査読有り][通常論文]
     
    Tyrosine kinase inhibitors (TKI) are used for primary therapy in patients with newly diagnosed CML. However, a reliable method for optimal selection of a TKI from the viewpoint of drug sensitivity of CML cells has not been established. We have developed a FRET-based drug sensitivity test in which a CrkL-derived fluorescent biosensor efficiently quantifies the kinase activity of BCR-ABL of living cells and sensitively evaluates the inhibitory activity of a TKI against BCR-ABL. Here, we validated the utility of the FRET-based drug sensitivity test carried out at diagnosis for predicting the molecular efficacy. Sixty-two patients with newly diagnosed chronic phase CML were enrolled in this study and treated with dasatinib. Bone marrow cells at diagnosis were subjected to FRET analysis. The ΔFRET value was calculated by subtraction of FRET efficiency in the presence of dasatinib from that in the absence of dasatinib. Treatment response was evaluated every 3 months by the BCR-ABL1 International Scale. Based on the ΔFRET value and molecular response, a threshold of the ΔFRET value in the top 10% of FRET efficiency was set to 0.31. Patients with ΔFRET value ≥0.31 had significantly superior molecular responses (MMR at 6 and 9 months and both MR4 and MR4.5 at 6, 9, and 12 months) compared with the responses in patients with ΔFRET value <0.31. These results suggest that the FRET-based drug sensitivity test at diagnosis can predict early and deep molecular responses. This study is registered with UMIN Clinical Trials Registry (UMIN000006358).
  • Shinjiro Fukami, Nobuyuki Nakajima, Hirofumi Okada, Jiro Akimoto, Tamotsu Miki, Hirokazu Fukuhara, Yukiko Shishido-Hara, Toshitaka Nagao, Masumi Tsuda, Michihiro Kohno
    World Neurosurgery 114 e366 - e377 2018年06月01日 [査読有り][通常論文]
     
    Introduction: Removal of midline paraventricular gliomas is difficult because of their deep localization and invasive character, requiring biopsy for pathologic diagnosis. This study aimed to assess the pathologic findings and clinical course of midline paraventricular gliomas diagnosed using a neuroendoscope. Methods: This study was performed as a retrospective investigation using a neuroendoscope of 26 patients whose tumors were diagnosed as midline paraventricular gliomas. The main loci of the lesions were the thalamus (11 patients), tectum (6 patients), and other areas (9 patients). Of these 26 patients, 21 (81%) had accompanying obstructive hydrocephalus. Surgery was performed via the lateral ventricle using a flexible scope. For patients with obstructive hydrocephalus, we added endoscopic third ventriculostomy, septostomy, and/or plasty of the foramen of Monro. Pathologic diagnosis was determined according to hematoxylin-eosin staining and immunohistochemistry using anti-GFAP, anti-Ki-67, anti-H3-K27M, and anti-IDH1-R132H antibodies. Results: The pathologic diagnoses were grade I (5 patients), grade II (3 patients), grade III (6 patients), and grade IV (4 patients) gliomas. Six patients were diagnosed as having high-grade glioma, which was difficult to distinguish between grade III and grade IV. Two patients were undiagnosable. H3-K27M was strongly positive in 8 of 15 patients with high-grade glioma. All patients with high-grade gliomas died or received best supportive care within 2 years after surgery. Conclusions: Neuroendoscopic surgery is useful for midline paraventricular gliomas in terms of the treatment of obstructive hydrocephalus, as well as pathologic diagnosis and genetic analysis, which are required under the World Health Organization 2016 classification.
  • Konishi Y, Kawamata F, Nishihara H, Homma S, Kato Y, Tsuda M, Kohsaka S, Einama T, Liu C, Yoshida T, Nagatsu A, Tanino M, Tanaka S, Kawamura H, Kamiyama T, Taketomi A
    Medical oncology (Northwood, London, England) 35 7 104  2018年06月 [査読有り][通常論文]
  • Ya Nan Ye, Martin Frauenlob, Lei Wang, Masumi Tsuda, Tao Lin Sun, Kunpeng Cui, Riku Takahashi, Huijie Zhang, Tasuku Nakajima, Takayuki Nonoyama, Takayuki Kurokawa, Shinya Tanaka, Jian Ping Gong
    Advanced Functional Materials 28 31 1801489  2018年06月 [査読有り][通常論文]
  • Tough and Self‐Recoverable Thin Hydrogel Membranes for Biological Applications
    Ye YN, Frauenlob M, Wang L, Tsuda M, Sun TL, Cui K, Takahashi R, Ahang HJ, Nakajima T, Nonoyama T, Kurokawa T, Tanaka S, Gong JP
    Advanced Functional Materials 29 1801489 1 - 11 2018年03月 [査読有り][通常論文]
  • Yachi K, Tsuda M, Kohsaka S, Wang L, Oda Y, Tanikawa S, Ohba Y, Tanaka S
    Signal transduction and targeted therapy 3 33  2018年 [査読有り][通常論文]
  • Tsuda Masumi, Yoshida Kazuhiko, Matsumoto Ryuji, Kondo Tsunenori, Shinohara Nobuo, Tanaka Shinya
    CANCER SCIENCE 109 121  2018年01月 [査読有り][通常論文]
  • Kawamata F, Nishihara H, Homma S, Kato Y, Tsuda M, Konishi Y, Wang L, Kohsaka S, Liu C, Yoshida T, Tanino M, Tanaka S, Kawamura H, Kamiyama T, Taketomi A
    The American journal of pathology 188 1 204 - 215 2018年01月 [査読有り][通常論文]
     
    Ectopic production of free β human chorionic gonadotropin (hCGβ) has been associated with aggressive behavior in non-trophoblastic tumors. hCGβ shares common evolutionary sequences with transforming growth factor-β (TGF-β), which represents a major driving force of epithelial-to-mesenchymal transition (EMT). In this study, we examined the biological roles of hCGβ during EMT and its clinical significance in colorectal cancer (CRC) progression. Eighty CRC specimens and 54 preoperative serum samples were analyzed. hCGβ-overexpressing human CRC cell lines were examined for invasiveness and tumorigenicity, and the expression of EMT-associated genes was investigated. In human CRC, histologic hCGβ positivity [13/80 (16.3%)] was lower than serologic hCGβ positivity [13/54 (24.1%)]. However, it was significantly correlated with several clinicopathological features and unfavorable outcome (P < 0.05). hCGβ-overexpressing cell lines had increased invasiveness, migratory ability, and metastatic potential in mice (P < 0.01). Western blot, PCR, and microarray analyses showed hCGβ altered expression of EMT-related genes, including E-cadherin, phosphorylated SMAD2, SNAIL, and TWIST. hCGβ-induced SNAIL and TWIST overexpression levels were reversible by type I and type II TGF-β receptor inhibitors (P < 0.05). hCGβ thus induces EMT via the TGF-β signaling pathway, and it may represent a molecular target in CRC treatment.
  • Marin Ishikawa, Mishie Ann Tanino, Masaya Miyazaki, Taichi Kimura, Yusuke Ishida, Lei Wang, Masumi Tsuda, Hiroshi Nishihara, Kazuo Nagashima, Shinya Tanaka
    Internal Medicine 57 10 1375 - 1380 2018年 [査読有り][通常論文]
     
    Objective Cardiovascular disease is a leading cause of sudden unexpected death even in hospitalized patients. Infectious aortitis is a rare disease that has the potential to cause aortic tears and hemorrhage followed by sudden death. The aim of this study was to reveal the clinicopathological features of infectious aortitis that are related to sudden unexpected death. Methods We retrospectively reviewed 1,310 autopsy cases over 15 years and selected the cases involving patients who died suddenly due to aortic tears. We analyzed the clinical information and pathological findings. Results One hundred thirty-three of 1,310 cases (10.2%) were autopsied under the clinical diagnosis of unexpected sudden death. Aortic tears were identified in 33 cases (2.5%) and infectious aortitis was diagnosed in 6 (18.2%) of these cases. All cases involved male patients (middle-aged to elderly) with risk factors for atherosclerosis (i.e., hypertension). The laboratory data showed continuous leukocytosis and C-reactive protein elevation, even during the improvement phase, in patients with pre-existing infectious disease. The autopsy findings revealed three types of aortic tears (aneurysms, dissections and penetrating atherosclerotic ulcers with moderate to severe atherosclerosis), and the infiltration of numerous neutrophils at the site of rupture. Gram-positive bacteria were detected in four cases and Gram-negative bacteria were detected in two cases. Discussion We demonstrated that sudden unexpected death caused by infectious aortitis rarely occurred in hospitalized patients, even in the recovery phase of the preceding infectious disease. We therefore recommend that clinicians pay attention to infectious aortitis in patients with infectious disease, particularly elderly patients with atherosclerotic disease, even those who are in the improvement phase. Conclusion Unexpected sudden death by infectious aortitis in the recovery phase of antecedent infection.
  • Naoya Inamura, Taichi Kimura, Lei Wang, Hiroko Yanagi, Masumi Tsuda, Mishie Tanino, Hiroshi Nishihara, Satoshi Fukuda, Shinya Tanaka
    AURIS NASUS LARYNX 44 4 447 - 457 2017年08月 [査読有り][通常論文]
     
    Objective: As 50% of patients of head and neck squamous carcinoma (HNSCC) exhibit poor prognosis, the identification of new therapeutic targets is required. Recently, there have been several reports about the correlation between Notch1 and HNSCC, but the precise mechanism is still obscure. Therefore, in this study, we examined the involvement of Notch I in HNSCC by using HNSCC cell lines and surgical specimens. Methods: To investigate the role of Notch1 in HNSCC, we examined the effect of Notch inhibitor DAPT on cell growth, invasion, and tumorigenicity using five HNSCC cell lines in vitro and in vivo. We further examined that the correlation with Notch expression and clinical prognostic factors was evaluated by using 101 HNSCC surgical specimens. Results: DAPT reduced the nuclear expression of Notch and c-Myc and repressed cell growth, EMT-dependent cell invasion in vitro, and tumorigenicity in vivo. An overexpression of Myc enhanced EMT with an increase of Snail and vimentin together with decreased levels of E-cadherin in HSC3 cells. Finally, we discovered that Notch expression was well correlated with MIB-1 index and lymph node metastases. Conclusion: We discovered that Notch1 was strongly correlated with HNSCC growth, invasion, and metastases. Therefore, Notch1 might be a new therapeutic target and a predictive marker of proliferation and metastasis of HNSCC. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
  • 森谷 純, 谷野 美智枝, 津田 真寿美, 田中 伸哉
    生体の科学 68 4 365 - 370 金原一郎記念医学医療振興財団 ; 1949- 2017年07月 [査読無し][通常論文]
  • Yoshida Kazuhiko, Tsuda Masumi, Matsumoto Ryuji, Semba Shingo, Kimura Taichi, Tanino Mishie, Nishihara Hiroshi, Kondo Tsunenori, Tanabe Kazunari, Tanaka Shinya
    JOURNAL OF UROLOGY 197 4 E1175  2017年04月 [査読有り][通常論文]
  • Marin Kato, Hiroshi Nishihara, Hideyuki Hayashi, Taichi Kimura, Yusuke Ishida, Lei Wang, Masumi Tsuda, Mishie Ann Tanino, Shinya Tanaka
    MEDICAL ONCOLOGY 34 1 8  2017年01月 [査読有り][通常論文]
     
    Sox10, one of the transcription factors, regulates Wnt/beta-catenin signaling in diverse developmental processes in normal tissues. Sox10 is also expressed in variable solid tumors such as breast cancer, salivary tumor, hepatocellular carcinoma, ovarian tumor, nasopharyngeal carcinoma, prostate cancer, and digestive cancer. The role of Sox10 during tumorigenesis is still controversial, especially in digestive cancers; thus, we performed clinicopathological evaluation of Sox10 expression in 41 cases of diffuse-type gastric adenocarcinoma (DGA). We examined the expression of Sox10 by immunohistochemical staining and real-time quantitative reverse transcriptase PCR and evaluated the correlation between Sox10 expression and clinicopathological factors. A low-level expression of Sox10 was significantly associated with high-level venous invasion by immunohistochemical evaluation, while it was significantly associated with high-level lymphatic permeation when analyzed by real-time PCR assay. Survival analysis of 41 cases indicated that high level of vascular permeation was a statistically poor prognostic factor, suggesting that derogation of Sox10 would lead to unfavorable patients' outcome through the acceleration of vascular invasion. In this study, we revealed the clinical benefit of evaluation of Sox10 expression to predict the risk of vascular permeation which yields patients' poor prognosis in DGA.
  • Satoshi Kawano, Alexandra R. Grassian, Masumi Tsuda, Sarah K. Knutson, Natalie M. Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M. Pollock, Jesse J. Smith, Kevin W. Kuntz, Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A. Copeland, Shinya Tanaka, Heike Keilhack
    PLOS ONE 12 1 e0170539  2017年01月 [査読有り][通常論文]
  • Matsumoto R, Tsuda M, Yoshida K, Tanino M, Kimura T, Nishihara H, Abe T, Shinohara N, Nonomura K, Tanaka S
    Scientific reports 6 34625 - 34625 2016年10月04日 [査読有り][通常論文]
     
    In treating bladder cancer, determining the molecular mechanisms of tumor invasion, metastasis, and drug resistance are urgent to improving long-term patient survival. One of the metabolic enzymes, aldo-keto reductase 1C1 (AKR1C1), plays an essential role in cancer invasion/metastasis and chemoresistance. In orthotopic xenograft models of a human bladder cancer cell line, UM-UC-3, metastatic sublines were established from tumors in the liver, lung, and bone. These cells possessed elevated levels of EMT-associated markers, such as Snail, Slug, or CD44, and exhibited enhanced invasion. By microarray analysis, AKR1C1 was found to be up-regulated in metastatic lesions, which was verified in metastatic human bladder cancer specimens. Decreased invasion caused by AKR1C1 knockdown suggests a novel role of AKR1C1 in cancer invasion, which is probably due to the regulation of Rac1, Src, or Akt. An inflammatory cytokine, interleukin-1β, was found to increase AKR1C1 in bladder cancer cell lines. One particular non-steroidal anti-inflammatory drug, flufenamic acid, antagonized AKR1C1 and decreased the cisplatin-resistance and invasion potential of metastatic sublines. These data uncover the crucial role of AKR1C1 in regulating both metastasis and drug resistance; as a result, AKR1C1 should be a potent molecular target in invasive bladder cancer treatment.
  • Sayaka Yuzawa, Hiroshi Nishihara, Lei Wang, Masumi Tsuda, Taichi Kimura, Mishie Tanino, Shinya Tanaka
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY 40 8 1031 - 1040 2016年08月 [査読有り][通常論文]
     
    Solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a mesenchymal tumor that can affect virtually any region of the body. SFT/HPC of the thoracic cavity and soft tissue has been histologically considered a single biological entity termed SFT; in fact, NAB2-STAT6 gene fusion was recently identified in both diseases. In contrast, meningeal SFT and HPC still need to be investigated in detail with regard to gene fusion variants. The aim of this study was to verify the frequency of NAB2-STAT6 fusion and the relationship between fusion variants and clinicopathologic findings of SFT/HPC, especially meningeal SFT/HPC. We examined the NAB2-STAT6 fusion by reverse transcription polymerase chain reaction with 4 cases of meningeal SFT and 13 cases of meningeal HPC. NAB2-STAT6 fusion transcripts were identified in 12 of 17 cases, including NAB2ex6-STAT6ex17 (4/17, 24%), NAB2ex6-STAT6ex16 and NAB2ex4-STAT6ex2 (3/17, 18%, respectively), and NAB2ex5-STAT6ex16 (2/17, 12%). Three cases showed a pseudopapillary pattern, and 2 of them carried NAB2ex6-STAT6ex17. In addition, our meta-analysis revealed that the major fusion variant in meningeal SFT/HPC was NAB2ex6-STAT6ex16/17 (29/54, 54%), which was also common in soft tissue and intraperitoneum/retroperitoneum but rare in thoracic SFT. Fusion variant significantly correlated with age and histologic diagnosis in meningeal SFT/HPC but not with prognosis. Our results represented that meningeal SFT and HPC were in a single biological spectrum with NAB2-STAT6 gene fusion as was nonmeningeal SFT and further confirmed the organ-specific tumorigenic process and morphologic differences on the basis of fusion variants in meningeal SFT/HPC.
  • Kimura T, Wang L, Tabu K, Tsuda M, Tanino M, Maekawa A, Nishihara H, Hiraga H, Taga T, Oda Y, Tanaka S
    Oncogene 35 30 3932 - 3943 Oncogene 2016年07月28日 [査読無し][通常論文]
     
    Synovial sarcoma accounts for almost 10% of all soft tissue sarcomas, and its prognosis is poor with 5-year survival rates at 36%. Thus, new treatments and therapeutic targets for synovial sarcoma are required. Tumor-initiating cells have been defined by the ability for self-renewal and multipotent differentiation, and they exhibit higher tumorigenic capacity, chemoresistance and radiation resistance, expecting to be a new therapeutic target. In synovial sarcoma, the presence of such stemness remains largely unclear; thus, we analyzed whether synovial sarcoma possessed tumor-initiating cells and explored specific markers, and we discovered that synovial sarcoma cell lines possessed heterogeneity by way of containing a sphere-forming subpopulation highly expressing NANOG, OCT4 and SOX2. By expression microarray analysis, CXCR4 was identified to be highly expressed in the sphere subpopulation and correlated with stem-cell-Associated markers. Inhibition of CXCR4 suppressed the cell proliferation of synovial sarcoma cell lines in vitro. The tumor-initiating ability of CXCR4-positive cells was demonstrated by xenograft propagation assay. CXCR4-positive cells showed higher tumorigenicity
  • Sayaka Yuzawa, Hiroshi Nishihara, Shigeru Yamaguchi, Hiromi Mohri, Lei Wang, Taichi Kimura, Masumi Tsuda, Mishie Tanino, Hiroyuki Kobayashi, Shunsuke Terasaka, Kiyohiro Houkin, Norihiro Sato, Shinya Tanaka
    MODERN PATHOLOGY 29 7 708 - 716 2016年07月 [査読有り][通常論文]
     
    Recent genetic analyses using next-generation sequencers have revealed numerous genetic alterations in various tumors including meningioma, which is the most common primary brain tumor. However, their use as routine laboratory examinations in clinical applications for tumor genotyping is not cost effective. To establish a clinical sequencing system for meningioma and investigate the clinical significance of genotype, we retrospectively performed targeted amplicon sequencing on 103 meningiomas and evaluated the association with clinicopathological features. We designed amplicon-sequencing panels targeting eight genes including NF2 (neurofibromin 2), TRAF7, KLF4, AKT1, and SMO. Libraries prepared with genomic DNA extracted from PAXgenefixed paraffin-embedded tissues of 103 meningioma specimens were sequenced using the Illumina MiSeq. NF2 loss in some cases was also confirmed by interphase-fluorescent in situ hybridization. We identified NF2 loss and/or at least one mutation in NF2, TRAF7, KLF4, AKT1, and SMO in 81 out of 103 cases (79%) by targeted amplicon sequencing. On the basis of genetic status, we categorized meningiomas into three genotype groups: NF2 type, TRAKLS type harboring mutation in TRAF7, AKT1, KLF4, and/or SMO, and 'not otherwise classified' type. Genotype significantly correlated with tumor volume, tumor location, and magnetic resonance imaging findings such as adjacent bone change and heterogeneous gadolinium enhancement, as well as histopathological subtypes. In addition, multivariate analysis revealed that genotype was independently associated with risk of recurrence. In conclusion, we established a rapid clinical sequencing system that enables final confirmation of meningioma genotype within 7 days turnaround time. Our method will bring multiple benefits to neuropathologists and neurosurgeons for accurate diagnosis and appropriate postoperative management.
  • Satoshi Kawano, Alexandra R. Grassian, Masumi Tsuda, Sarah K. Knutson, Natalie M. Warholic, Galina Kuznetsov, Shanqin Xu, Yonghong Xiao, Roy M. Pollock, Jesse S. Smith, Kevin K. Kuntz, Scott Ribich, Yukinori Minoshima, Junji Matsui, Robert A. Copeland, Shinya Tanaka, Heike Keilhack
    PLOS ONE 11 7 e0158888  2016年07月 [査読有り][通常論文]
     
    The catalytic activities of covalent and ATP-dependent chromatin remodeling are central to regulating the conformational state of chromatin and the resultant transcriptional output. The enzymes that catalyze these activities are often contained within multiprotein complexes in nature. Two such multiprotein complexes, the polycomb repressive complex 2 (PRC2) methyltransferase and the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeler have been reported to act in opposition to each other during development and homeostasis. An imbalance in their activities induced by mutations/deletions in complex members (e.g. SMARCB1) has been suggested to be a pathogenic mechanism in certain human cancers. Here we show that preclinical models of synovial sarcoma-a cancer characterized by functional SMARCB1 loss via its displacement from the SWI/SNF complex through the pathognomonic SS18-SSX fusion protein-display sensitivity to pharmacologic inhibition of EZH2, the catalytic subunit of PRC2. Treatment with tazemetostat, a clinicalstage, selective and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity reverses a subset of synovial sarcoma gene expression and results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX fusion-positive cells in vitro. Treatment of mice bearing either a cell line or two patient-derived xenograft models of synovial sarcoma leads to dose-dependent tumor growth inhibition with correlative inhibition of trimethylation levels of the EZH2-specific substrate, lysine 27 on histone H3. These data demonstrate a dependency of SS18-SSX-positive, SMARCB1-deficient synovial sarcomas on EZH2 enzymatic activity and suggests the potential utility of EZH2-targeted drugs in these genetically defined cancers.
  • Elmansuri AZ, Tanino MA, Mahabir R, Wang L, Kimura T, Nishihara H, Kinoshita I, Dosaka-Akita H, Tsuda M, Tanaka S
    Oncotarget 7 19 27094 - 27107 2016年05月 [査読有り][通常論文]
     
    The signaling adaptor protein Crk has been shown to play an important role in various human cancers. However, its regulatory machinery is not clear. Here, we demonstrated that Crk induced EMT in A549 human lung adenocarcinoma cells through differential regulation of Rac1/Snail and RhoA/Slug, leading to decreased expression of E-cadherin and increased N-cadherin, fibronectin, and MMP2 expression. Cancer cells with mesenchymal features produced TGF-beta and also increased the levels of TGF-beta receptor. TGF-beta increased the endogenous levels of Crk and also augmented Crk-dependent expression of Snail and Slug, and conversely TGF-beta receptor inhibitor suppressed the levels of Snail and Slug. Overexpression of Crk was observed at the invasive front of human lung cancer tissues and was significantly associated with poor prognosis. Thus, TGF-beta and Crk collaborate to form a positive feedback loop to facilitate EMT, which may lead to the malignancy of human cancers possibly being affected by their microenvironment.
  • Keiko Goto, Taichi Kimura, Nobuto Kitamura, Shingo Semba, Yoshihiro Ohmiya, Sachiyo Aburatani, Satoko Matsukura, Masumi Tsuda, Takayuki Kurokawa, Jian Ping Gong, Shinya Tanaka, Kazunori Yasuda
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A 104 3 734 - 746 2016年03月 [査読有り][通常論文]
     
    The purposes of this study were to identify signaling pathways that were specifically activated in ATDC5 cells cultured on poly (2-acrylamido-2-methylpropanesulfonic acid) (PAMPS) gel in insulin-free maintenance medium and to evaluate the significance of the determined signaling pathways in the chondrogenic differentiation induced by this gel. In this study, ATDC5 cells cultured on PAMPS gel using the maintenance medium without insulin (PAMPS Culture) were compared with cells cultured on polystyrene using the differentiation medium containing insulin (PS-I Culture). The microarray analysis, Western blot analysis, and real-time PCR analysis demonstrated that the TGF-/BMP signaling pathway was significantly enhanced at Days 1, 2, and 3 in the PAMPS Culture when compared with the PS-I Culture. Inhibition of the BMP type-I receptor reduced the phosphorylation level of Smad1/5 and expression of type-2 collagen and aggrecan mRNA in the cells accompanied by a reduction in cell aggregation at Day 13 in the PAMPS Culture. The inhibition of the TGF-/BMP signaling pathway significantly inhibited the chondrogenic differentiation induced by the PAMPS gel. The present study demonstrated that synthetic PAMPS gel activates the TGF-/BMP/Smad signaling pathway in the ATDC5 cells in the absence of insulin, and that this activation plays a significant role in the chondrogenic differentiation induced by PAMPS gel. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 734-746, 2016.
  • Yamada T, Tsuda M, Wagatsuma T, Fujioka Y, Fujioka M, Satoh AO, Horiuchi K, Nishide S, Nanbo A, Totsuka Y, Haga H, Tanaka S, Shindoh M, Ohba Y
    Scientific reports 6 23545  2016年03月 [査読有り][通常論文]
     
    Cellular interactions with the extracellular matrix play critical roles in tumor progression. We previously reported that receptor activator of NF-kappa B ligand (RANKL) specifically facilitates head and neck squamous cell carcinoma (HNSCC) progression in vivo. Here, we report a novel role for RANKL in the regulation of cell adhesion. Among the major type I collagen receptors, integrin alpha 2 was significantly upregulated in RANKL-expressing cells, and its knockdown suppressed cell adhesion. The mRNA abundance of integrin alpha 2 positively correlated with that of RANKL in human HNSCC tissues. We also revealed that RANK-NF-kappa B signaling mediated integrin alpha 2 expression in an autocrine/paracrine manner. Interestingly, the amount of active integrin beta 1 on the cell surface was increased in RANKL-expressing cells through the upregulation of integrin alpha 2 and endocytosis. Moreover, the RANK-integrin alpha 2 pathway contributed to RANKL-dependent enhanced survival in a collagen gel and inhibited apoptosis in a xenograft model, demonstrating an important role for RANKL-mediated cell adhesion in three-dimensional environments.
  • Takayuki Inuzuka, Yoichiro Fujioka, Masumi Tsuda, Mari Fujioka, Aya O. Satoh, Kosui Horiuchi, Shinya Nishide, Asuka Nanbo, Shinya Tanaka, Yusuke Ohba
    SCIENTIFIC REPORTS 6 21613  2016年02月 [査読有り][通常論文]
     
    Angiotensin II (AII) type 2 receptor (AT2R) negatively regulates type 1 receptor (AT1R) signaling. However, the precise molecular mechanism of AT2R-mediated AT1R inhibition remains poorly understood. Here, we characterized the local and functional interaction of AT2R with AT1R. AT2R colocalized and formed a complex with AT1R at the plasma membrane, even in the absence of AII. Upon AII stimulation, the spatial arrangement of the complex was modulated, as confirmed by Forster resonance energy transfer (FRET) analysis, followed by AT2R internalization along with AT1R. AT2R internalization was specifically observed only in the presence of AT1R; AT2R alone could not be internalized. The AT1R-specific inhibitor losartan completely inhibited both the conformational change and the internalization of AT2R with AT1R, whereas the AT2R-specific inhibitor PD123319 partially hindered these phenomena, demonstrating that the activation of both receptors was indispensable for these effects. In addition, treatment with the protein kinase C (PKC) inhibitors inhibited the ligand-dependent accumulation of AT2R but not that of AT1R in the endosomes. A mutation in the putative phosphorylation sites of AT2R also abrogated the co-internalization of ATR2 with AT1R and the inhibitory effect of ATR2 on AT1R. These data suggest that AT2R inhibits ligand-induced AT1R signaling through the PKC-dependent pathway.
  • Jun Moriya, Mishie Ann Tanino, Tomoko Takenami, Tomoko Endoh, Masana Urushido, Yasutaka Kato, Lei Wang, Taichi Kimura, Masumi Tsuda, Hiroshi Nishihara, Shinya Tanaka
    BRAIN TUMOR PATHOLOGY 33 1 13 - 18 2016年01月 [査読有り][通常論文]
     
    The role of intraoperative pathological diagnosis for central nervous system (CNS) tumors is crucial for neurosurgery when determining the surgical procedure. Especially, treatment of carmustine (BCNU) wafers requires a conclusive diagnosis of high-grade glioma proven by intraoperative diagnosis. Recently, we demonstrated the usefulness of rapid immunohistochemistry (R-IHC) that facilitates antigen-antibody reaction under alternative current (AC) electric field in the intraoperative diagnosis of CNS tumors; however, a higher proportion of water and lipid in the brain parenchyma sometimes leads to freezing artifacts, resulting in poor quality of frozen sections. On the other hand, squash smear preparation of CNS tumors for cytology does not affect the frozen artifacts, and the importance of smear preparation is now being re-recognized as being better than that of the tissue sections. In this study, we established the rapid immunocytochemistry (R-ICC) protocol for squash smears of CNS tumors using AC electric field that takes only 22 min, and demonstrated its usefulness for semi-quantitative Ki-67/MIB-1 labeling index and CD 20 by R-ICC for intraoperative diagnosis. R-ICC by AC electric field may become a substantial tool for compensating R-IHC and will be applied for broad antibodies in the future.
  • Tamio Ito, Kenichi Sato, Mitsuteru Oikawa, Hironori Sugio, Taku Asanome, Yoshimaru Ozaki, Hirohiko Nakamura, Shinya Tanaka, Masumi Tsuda, Kazuo Nagashima
    Neurological Surgery 43 9 825 - 833 2015年09月01日 [査読有り][通常論文]
     
    In contrast to pilocytic astrocytomas (PAs), pilomyxoid astrocytomas (PMAs) demonstrate monophasic piloid cells with angiocentric distribution and a more aggressive clinical course. Recently, several reports have described combined histological features of both subtypes accordingly, these were termed intermediate pilomyxoid tumors (IPTs). The KIAA1549-BRAF fusion gene has been found in approximately 70% of PAs, but is reportedly rare in PMAs. We describe a clinicopathological study of two patients with pilomyxoid-spectrum astrocytoma (PMSA). Case 1 was of a 29-year-old man who presented with a generalized seizure. Gadolinium-magnetic resonance imaging (Gd-MRI) demonstrated a less enhanced tumor in the left temporal lobe. Case 2 was of a 9-year-old boy who presented with headache. Gd-MRI revealed an irregularly enhanced tumor in the left cerebellum. In Case 1, the tumor showed monomorphous bipolar cells in a myxoid background and angiocentric arrangement therefore, the diagnosis was PMA. In Case 2, part of the tumor had a myxoid, angiocentric pattern characteristic of PMA the other part had a biphasic pattern characteristic of PA. PMA and PA were mixed in a 7:3 ratio therefore, IPT was diagnosed. No BRAF V600E mutations were found by immunohistochemistry and sequencing in either case. Three major KIAA1549-BRAF fusion subtypes were analyzed by quantitative reverse transcription polymerase chain reaction (RT-PCR) and sequencing. No fusions were found in Case 1. However, K16-B9 fusion was identified in Case 2, and this fusion was more prevalent in the PA component than in the PMA component. In summary, no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in IPT, particularly in the PA component.
  • Jun-ichi Furukawa, Masumi Tsuda, Kazue Okada, Taichi Kimura, Jinhua Piao, Shinya Tanaka, Yasuro Shinohara
    PLOS ONE 10 7 e0128300  2015年07月 [査読有り][通常論文]
     
    Cancer cells frequently express glycans at different levels and/or with fundamentally different structures from those expressed by normal cells, and therefore elucidation and manipulation of these glycosylations may provide a beneficial approach to cancer therapy. However, the relationship between altered glycosylation and causal genetic alteration(s) is only partially understood. Here, we employed a unique approach that applies comprehensive glycomic analysis to a previously described multistep tumorigenesis model. Normal human astrocytes were transformed via the serial introduction of hTERT, SV40ER, HRasV12, and myrAKT, thereby mimicking human brain tumor grades I-IV. More than 160 glycans derived from three major classes of cell surface glycoconjugates (N-and O-glycans on glycoproteins, and glycosphingolipids) were quantitatively explored, and specific glycosylation patterns related to malignancy were systematically identified. The sequential introduction of hTERT, SV40ER, H-RasV12, and myrAKT led to (i) temporal expression of pauci-mannose/mono-antennary type N-glycans and GD3 (hTERT); (ii) switching from ganglio-to globo-series glycosphingolipids and the appearance of Neu5Gc (hTERT and SV40ER); (iii) temporal expression of bisecting GlcNAc residues, a2,6-sialylation, and stage-specific embryonic antigen-4, accompanied by suppression of core 2 O-glycan biosynthesis (hTERT, SV40ER and Ras); and (iv) increased expression of (neo) lacto-series glycosphingolipids and fucosylated N-glycans (hTERT, SV40ER, Ras and AKT). These sequential and transient glycomic alterations may be useful for tumor grade diagnosis and tumor prognosis, and also for the prediction of treatment response.
  • Yoshinori Makino, Masumi Tsuda, Yusuke Ohba, Hiroshi Nishihara, Hirofumi Sawa, Kazuo Nagashima, Shinya Tanaka
    CELL COMMUNICATION AND SIGNALING 13 35  2015年07月 [査読有り][通常論文]
     
    Background: The complex of Dock180/ELMO1 that functions as a bipartite guanine nucleotide exchange factor for Rac is essential for diverse physiological and pathological processes of cells such as cell migration, phagocytosis, and invasion of cancer cells. Among the Src-family tyrosine kinases (SFKs), it has been reported that Hck directly phosphorylates ELMO1, regulating phagocytosis by promoting activation of Rac1; however, the involvement of other SFKs in ELMO1 phosphorylation has remained unknown. Here, we identified novel tyrosine (Y) residues of ELMO1 phosphorylated by SFKs, and examined the effects on Rac1 activity, cell adhesion, spreading, and cell motility on extracellular matrix (ECM). Results: In this study, we unveiled that Src and Fyn can induce tyrosine phosphorylation of ELMO1 in in vivo and in vitro phosphorylation assays. Mutational analyses identified both Y720 and Y724 residues of ELMO1 as Src-mediated phosphorylation sites, preferentially on Y724. Single substitution of Y724 to Phe abrogated Rac1 activation triggered by Src. To elucidate the biological function of pY724, we established NIH3T3 cells stably expressing wild-type ELMO1 or its Y724F mutant together with Dock180. Among them, Y724-deficient cells exhibited a depletion of Rac1 activity with diminished phosphorylation of ELMO1 even upon the ECM-stimulation. It is noteworthy that NIH3T3 cells with ELMO1 Y724F were strikingly defective to promote cell spreading on fibronectin-coated dish, concomitantly exhibiting immature assemblies of actin stress fibers and focal adhesions. Eventually, ELMO1 Y724F significantly impaired cell migration. Conclusion: These results define that Src-mediated Y724 phosphorylation in ELMO1 plays a critical role for cell spreading via activation of Rac1, leading to promotion of cell migration. As the overexpression and/or hyperactivation of Src have been shown in a wide variety of human cancers, Src-mediated phosphorylation of Y724 in ELMO1 may regulate cancer cell adhesion to the ECM, invasion into surrounding tissues, and subsequent distant metastasis.
  • Ryuji Matsumoto, Masumi Tsuda, Lei Wang, Nako Maishi, Takashige Abe, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Kyoko Hida, Yusuke Ohba, Nobuo Shinohara, Katsuya Nonomura, Shinya Tanaka
    Cancer science 106 6 709 - 17 2015年06月 [査読有り][通常論文]
     
    We have previously reported that an adaptor protein CRK, including CRK-I and CRK-II, plays essential roles in the malignant potential of various aggressive human cancers, suggesting the validity of targeting CRK in molecular targeted therapy of a wide range of cancers. Nevertheless, the role of CRK in human bladder cancer with marked invasion, characterized by distant metastasis and poor prognosis, remains obscure. In the present study, immunohistochemistry indicated a striking enhancement of CRK-I/-II, but not CRK-like, in human bladder cancer tissues compared to normal urothelium. We established CRK-knockdown bladder cancer cells using 5637 and UM-UC-3, which showed a significant decline in cell migration, invasion, and proliferation. It is noteworthy that an elimination of CRK conferred suppressed phosphorylation of c-Met and the downstream scaffold protein Gab1 in a hepatocyte growth factor-dependent and -independent manner. In epithelial-mesenchymal transition-related molecules, E-cadherin was upregulated by CRK elimination, whereas N-cadherin, vimentin, and Zeb1 were downregulated. A similar effect was observed following treatment with c-Met inhibitor SU11274. Depletion of CRK significantly decreased cell proliferation of 5637 and UM-UC-3, consistent with reduced activity of ERK. An orthotopic xenograft model with bioluminescent imaging revealed that CRK knockdown significantly attenuated not only tumor volume but also the number of circulating tumor cells, resulted in a complete abrogation of metastasis. Taken together, this evidence uncovered essential roles of CRK in invasive bladder cancer through the hepatocyte growth factor/c-Met/CRK feedback loop for epithelial-mesenchymal transition induction. Thus, CRK might be a potent molecular target in bladder cancer, particularly for preventing metastasis, leading to the resolution of clinically longstanding critical issues.
  • Matsumoto Ryuji, Tsuda Masumi, Abe Takashige, Maruyama Satoru, Tsuchiya Kunihiko, Miyajima Naoto, Shinohara Nobuo, Tanaka Shinya
    JOURNAL OF UROLOGY 193 4 E535  2015年04月 [査読有り][通常論文]
  • Y. Fujioka, M. Tsuda, A. Nanbo, T. Hattori, J. Sasaki, T. Sasaki, T. Miyazaki, Y. Ohba
    MOLECULAR BIOLOGY OF THE CELL 25 2014年12月 [査読有り][通常論文]
  • Yusuke Minami, Shinji Kohsaka, Masumi Tsuda, Kazuhiro Yachi, Nobuaki Hatori, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, Akio Minami, Norimasa Iwasaki, Shinya Tanaka
    CANCER SCIENCE 105 9 1152 - 1159 2014年09月 [査読有り][通常論文]
     
    MicroRNA (miRNA) can function as tumor suppressors or oncogenes, and also as potential specific cancer biomarkers; however, there are few published studies on miRNA in synovial sarcomas, and their function remains unclear. We transfected the OncomiR miRNA Precursor Virus Library into synovial sarcoma Fuji cells followed by a colony formation assay to identify miRNAs to confer an aggressive tumorigenicity, and identified miR-17-5p from the large colonies. MiR-17 was found to be induced by a chimeric oncoprotein SS18-SSX specific for synovial sarcoma, and all examined cases of human synovial sarcoma expressed miR-17, even at high levels in several cases. Overexpression of miR-17 in synovial sarcoma cells, Fuji and HS-SYII, increased colony forming ability in addition to cell growth, but not cell motility and invasion. Tumor volume formed in mice in vivo was significantly increased by miR-17 overexpression with a marked increase of MIB-1 index. According to PicTar and Miranda algorithms, which predicted CDKN1A (p21) as a putative target of miR-17, a luciferase assay was performed and revealed that miR-17 directly targets the 3-UTR of p21 mRNA. Indeed, p21 protein level was remarkably decreased by miR-17 overexpression in a p53-independent manner. It is noteworthy that miR-17 succeeded in suppressing doxorubicin-evoked higher expression of p21 and conferred the drug resistance. Meanwhile, introduction of anti-miR-17 in Fuji and HS-SYII cells significantly decreased cell growth, consistent with rescued expression of p21. Taken together, miR-17 promotes the tumor growth of synovial sarcomas by post-transcriptional suppression of p21, which may be amenable to innovative therapeutic targeting in synovial sarcoma.
  • Shinji Kohsaka, Kunihiko Hinohara, Lei Wang, Tatsunori Nishimura, Masana Urushido, Kazuhiro Yachi, Masumi Tsuda, Mishie Tanino, Taichi Kimura, Hiroshi Nishihara, Noriko Gotoh, Shinya Tanaka
    NEURO-ONCOLOGY 16 7 960 - 970 2014年07月 [査読有り][通常論文]
     
    Glioblastoma multiforme (GBM) is one of the most aggressive human tumors, and the establishment of an effective therapeutic reagent is a pressing priority. Recently, it has been shown that the tumor tissue consists of heterogeneous components and that a highly aggressive population should be the therapeutic target. Through a single subcutaneous passage of GBM cell lines LN443 and U373 in mice, we have developed highly aggressive variants of these cells named LN443X, U373X1, and U373X2, which showed increased tumor growth, colony-forming potential, sphere-forming potential, and invasion ability. We further investigated using microarray analysis comparing malignant cells with their parental cells and mRNA expression analysis in grades II to IV glioma samples. Adipocyte enhancer binding protein 1, epiregulin (EREG), and microfibrillar associated protein 5 were identified as candidate genes associated with higher tumor grade and poor prognosis. Immunohistochemical analysis also indicated a correlation of a strong expression of EREG with short overall survival. Furthermore, both EREG stimulation and EREG introduction of GBM cell lines were found to increase phosphorylation of epidermal growth factor receptor (EGFR) and extracellular signal-regulated kinase and resulted in the promotion of colony formation, sphere formation, and in vivo tumor formation. Gefitinib treatment inhibited phosphorylation of EGFR and extracellular signal-regulated kinase and led to tumor regression in U373-overexpressed EREG. These results suggested that EREG is one of the molecules involved in glioma malignancy, and EGFR inhibitors may be a candidate therapeutic agent for EREG-overexpressing GBM patients.
  • Roshan Mahabir, Mishie Tanino, Aiman Elmansuri, Lei Wang, Taichi Kimura, Tamio Itoh, Yusuke Ohba, Hiroshi Nishihara, Hiroki Shirato, Masumi Tsuda, Shinya Tanaka
    NEURO-ONCOLOGY 16 5 671 - 685 2014年05月 [査読有り][通常論文]
     
    Ionizing irradiation is an effective treatment for malignant glioma (MG); however, a higher rate of recurrence with more aggressive phenotypes is a vital issue. Although epithelial-mesenchymal transition (EMT) is involved in irradiation-induced cancer progression, the role for such phenotypic transition in MG remains unknown. To investigate the mechanism of irradiation-dependent tumor progression in MG, we performed immunohistochemistry (IHC) and qRT-PCR using primary and recurrent MG specimens, MG cell lines, and primary culture cells of MG. siRNA technique was used for MG cell lines. In 22 cases of clinically recurrent MG, the expression of the mesenchymal markers vimentin and CD44 was found to be increased by IHC. In paired identical MG of 7 patients, the expression of collagen, MMPs, and YKL-40 were also elevated in the recurrent MGs, suggesting the The Cancer Genome Atlas-based mesenchymal subtype. Among EMT regulators, sustained elevation of Snail was observed in MG cells at 21 days after irradiation. Cells exhibited an upregulation of migration, invasion, numbers of focal adhesion, and MMP-2 production, and all of these mesenchymal features were abrogated by Snail knockdown. Intriguingly, phosphorylation of ERK1/2 and GSK-3 were increased after irradiation in a Snail-dependent manner, and TGF- was elevated in both fibroblasts and macrophages but not in MG cells after irradiation. It was noteworthy that irradiated cells also expressed stemness features such as SOX2 expression and tumor-forming potential in vivo. We here propose a novel concept of glial-mesenchymal transition after irradiation in which the sustained Snail expression plays an essential role.
  • Kenta Takahashi, Masumi Tsuda, Hiromi Kanno, Junichi Murata, Roshan Mahabir, Yusuke Ishida, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Kazuo Nagashima, Shinya Tanaka
    BRAIN TUMOR PATHOLOGY 31 2 118 - 123 2014年04月 [査読有り][通常論文]
     
    Small cell glioblastoma is a histological subtype of glioblastoma with characteristic features of highly proliferative, monotonous small glial cells with high nuclear cytoplasm ratio. Morphologically, malignant lymphoma or small cell metastatic carcinoma should be carefully discriminated. Some cases are difficult to differentiate from anaplastic oligodendroglioma. In this report, we present a case of small cell glioblastoma of an elderly man. The lack of IDH1/2 mutation was confirmed by immunohistochemistry and direct sequencing. Fluorescence in situ hybridization revealed the lower rates of chromosome 1p and 19q deletion. Microsatellite analysis disclosed partial 10q alteration near the PTEN locus. Not only morphological and immunohistochemical examinations, but also cytogenetical investigations for IDH1/2 mutation, 1p/19q loss, and PTEN alteration, are strongly supportive methods for the differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma.
  • Futoshi Kawamata, Shigenori Homma, Hirofumi Kamachi, Takahiro Einama, Yasutaka Kato, Masumi Tsuda, Shinya Tanaka, Masahiro Maeda, Kazunori Kajino, Okio Hino, Norihiko Takahashi, Toshiya Kamiyama, Hiroshi Nishihara, Akinobu Taketomi, Satoru Todo
    JOURNAL OF GASTROENTEROLOGY 49 1 81 - 92 2014年01月 [査読有り][通常論文]
     
    Background Lymph node metastasis is a key event of colorectal cancer (CRC) progression. Mesothelin is expressed in various types of malignant tumor and associated with an unfavorable prognosis. The full-length mesothelin (Full-ERC) is cleaved by protease into membrane-bound C-ERC/mesothelin and N-ERC/mesothelin which is secreted into the blood. The aim of this study was to examine the biological role of mesothelin in CRC by clinicopathological analysis and in vitro lymphatic invasion assay. Methods Ninety-one cases of CRC specimens were immunohistochemically examined and the localization of mesothelin in luminal membrane and/or cytoplasm was also evaluated. Lymphatic invasion assay was also performed using the human CRC cell line, WiDr, which was transfected with Full-, N- and C-ERC/mesothelin expression plasmids (Full-WiDr, N-WiDr and C-WiDr). Results Immunohistochemically, "luminal membrane positive" of mesothelin was identified in 37.4 %, and correlated with lymphatic permeation and lymph node metastasis, but not with patients' prognosis. Interestingly, among the patients with lymph node metastasis (N = 38), "luminal membrane positive" of mesothelin significantly correlated with unfavorable patients' outcome. In addition, lymphatic invasion assay revealed that Full-WiDr and C-WiDr more significantly invaded human lymphatic endothelial cells than the Mock-WiDr (P < 0.01). Conclusion The luminal membrane expression of mesothelin was associated with unfavorable prognosis of CRC patients with lymph nodemetastasis. Moreover, this is the first report to prove the biological function of C-ERC/mesothelin associated with lymphatic invasion of cancer in vitro.
  • Masaya Miyazaki, Hiroshi Nishihara, Hideki Hasegawa, Masato Tashiro, Lei Wang, Taichi Kimura, Mishie Tanino, Masumi Tsuda, Shinya Tanaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 441 4 953 - 957 2013年11月 [査読有り][通常論文]
     
    The influenza A virus non-structural protein 1 (NS1) is a multifunctional virulence factor consisting of an RNA binding domain and several Src-homology (SH) 2 and SH3 binding motifs, which promotes virus replication in the host cell and helps to evade antiviral immunity. NS1 modulates general host cell physiology in association with various cellular molecules including NS1-binding protein (NS1-BP) and signaling adapter protein CRK-like (CRKL), while the physiological role of NS1-BP during influenza A virus infection especially in association with NS1 remains unclear. In this study, we analyzed the intracellular association of NS1-BP, NS1 and CRKL to elucidate the physiological roles of these molecules in the host cell. In HEK293T cells, enforced expression of NS1 of A/Beijing (H1N1) and A/Indonesia (H5N1) significantly induced excessive phosphorylation of ERR and elevated cell viability, while the over-expression of NS1-BP and the abrogation of CRKL using siRNA abolished such survival effect of NS1. The pull-down assay using GST-fusion CRKL revealed the formation of intracellular complexes of NS1-BP, NS1 and CRKL. In addition, we identified that the N-terminus SH3 domain of CRKL was essential for binding to NS1-BP using GST-fusion CRKL-truncate mutants. This is the first report to elucidate the novel function of NS1-BP collaborating with viral protein NS1 in modulation of host cell physiology. In addition, an alternative role of adaptor protein CRKL in association with NS1 and NS1-BP during influenza A virus infection is demonstrated. (C) 2013 Elsevier Inc. All rights reserved.
  • Yoichiro Fujioka, Masumi Tsuda, Asuka Nanbo, Tomoe Hattori, Junko Sasaki, Takehiko Sasaki, Tadaaki Miyazaki, Yusuke Ohba
    NATURE COMMUNICATIONS 4 2763  2013年11月 [査読有り][通常論文]
     
    Various viruses enter host cells via endocytosis, but the molecular mechanisms underlying the specific internalization pathways remain unclear. Here we show that influenza A viruses (IAVs) enter cells via redundant pathways of clathrin-mediated and clathrin-independent endocytosis, with intracellular Ca2+ having a central role in regulation of both pathways by activating a signalling axis comprising RhoA, Rho-kinase, phosphatidylinositol 4-phosphate 5-kinase (PIP5K) and phospholipase C (PLC). IAV infection induces oscillations in the cytosolic Ca2+ concentration of host cells, the prevention of which markedly attenuates virus internalization and infection. The small GTPase RhoA is found both to function downstream of the virus-induced Ca2+ response and itself to induce Ca2+ oscillations in a manner dependent on Rho-kinase and subsequent PIP5K-PLC signalling. This signalling circuit regulates both clathrin-mediated and clathrin-independent endocytosis during virus infection and seems to constitute a key mechanism for regulation of IAV internalization and infection.
  • Hiromi Kanno, Hiroshi Nishihara, Lei Wang, Sayaka Yuzawa, Hiroyuki Kobayashi, Masumi Tsuda, Taichi Kimura, Mishie Tanino, Shunsuke Terasaka, Shinya Tanaka
    NEURO-ONCOLOGY 15 7 853 - 864 2013年07月 [査読有り][通常論文]
     
    Background. CD163 is a 130-kDa transmembrane protein expressed in human monocytes and macrophages, and the aberrant expression of CD163 in breast and colorectal cancer associated with patients' poor prognosis was reported. Here, we analyzed the expression of CD163 in meningioma, a common intracranial tumor, and its molecular mechanism in association with meningioma progression. Methods. First, we performed immunohistochemical analysis using 50 human meningioma specimens. Next, we established CD163-overexpressing human meningioma cell lines and investigated its roles in tumor progression in vitro and in vivo. Results. Immunohistochemically, 26 of 50 human meningioma specimens (52.0%) were positive for CD163 in tumor cells, including benign grade I (48.5%) and grade II (71.4%) cases. Furthermore, CD163 expression was correlated with histological atypical parameters that directly predict the prognosis of meningioma. CD163-overexpressing meningioma cells showed significant suppression of apoptosis and accelerated tumor growth in nude mice. In addition, unexpected splenomegaly affiliated with the xenograft predicted tumor-derived granulocyte colony-stimulating factor (G-CSF) production, which was confirmed by reverse-transcription polymerase chain reaction and enzyme-linked immunosorbent assay. Conclusions. To our knowledge, this is the first report that demonstrates CD163 expression in meningioma not only by immunohistochemistry but also by reverse-transcription polymerase chain reaction, using primary culture cells, and provides the novel molecular function of CD163 to prevent apoptosis through the production of G-CSF in meningioma.
  • Rachel Kobos, Makoto Nagai, Masumi Tsuda, Man Yee Merl, Tsuyoshi Saito, Marick Lae, Qianxing Mo, Adam Olshen, Steven Lianoglou, Christina Leslie, Irina Ostrovnaya, Christophe Antczak, Hakim Djaballah, Marc Ladanyi
    JOURNAL OF PATHOLOGY 229 5 743 - 754 2013年04月 [査読有り][通常論文]
     
    Oncogenic rearrangements of the TFE3 transcription factor gene are found in two distinct human cancers. These include ASPSCR1TFE3 in all cases of alveolar soft part sarcoma (ASPS) and ASPSCR1TFE3, PRCC-TFE3, SFPQ-TFE3 and others in a subset of paediatric and adult RCCs. Here we examined the functional properties of the ASPSCR1TFE3 fusion oncoprotein, defined its target promoters on a genome-wide basis and performed a high-throughput RNA interference screen to identify which of its transcriptional targets contribute to cancer cell proliferation. We first confirmed that ASPSCR1TFE3 has a predominantly nuclear localization and functions as a stronger transactivator than native TFE3. Genome-wide location analysis performed on the FU-UR-1 cell line, which expresses endogenous ASPSCR1TFE3, identified 2193 genes bound by ASPSCR1TFE3. Integration of these data with expression profiles of ASPS tumour samples and inducible cell lines expressing ASPSCR1TFE3 defined a subset of 332 genes as putative up-regulated direct targets of ASPSCR1TFE3, including MET (a previously known target gene) and 64 genes as down-regulated targets of ASPSCR1TFE3. As validation of this approach to identify genuine ASPSCR1TFE3 target genes, two up-regulated genes bound by ASPSCR1TFE3, CYP17A1 and UPP1, were shown by multiple lines of evidence to be direct, endogenous targets of transactivation by ASPSCR1TFE3. As the results indicated that ASPSCR1TFE3 functions predominantly as a strong transcriptional activator, we hypothesized that a subset of its up-regulated direct targets mediate its oncogenic properties. We therefore chose 130 of these up-regulated direct target genes to study in high-throughput RNAi screens, using FU-UR-1 cells. In addition to MET, we provide evidence that 11 other ASPSCR1TFE3 target genes contribute to the growth of ASPSCR1TFE3-positive cells. Our data suggest new therapeutic possibilities for cancers driven by TFE3 fusions. More generally, this work establishes a combined integrated genomics/functional genomics strategy to dissect the biology of oncogenic, chimeric transcription factors. Copyright (c) 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • Kenta Takahashi, Yasuko Orba, Taichi Kimura, Lei Wang, Shinji Kohsaka, Masumi Tsuda, Mishie Tanino, Hiroshi Nishihara, Kazuo Nagashima, Hirofumi Sawa, Shinya Tanaka
    JAPANESE JOURNAL OF INFECTIOUS DISEASES 66 2 126 - 132 2013年03月 [査読有り][通常論文]
     
    JC virus (JCV) is a causative agent of progressive multifocal leukoencephalopathy (PML). Methyl CpG binding protein 2 (MeCP2) is a transcriptional control nuclear protein that is abundantly expressed in neurons. We previously observed that the MeCP2 protein is expressed in JCV large T antigen (TAg)-expressing glial cells in PML brains. To investigate the relationship between MeCP2 and JCV TAg, we examined the promoter activity and mRNA and protein expression levels of MeCP2 in JCV TAg-expressing cells. We found that JCV TAg enhances the promoter activity of MeCP2, but does not enhance the mRNA and protein levels of MeCP2. These results suggest that post-transcriptional mechanisms may play a role in MeCP2 expression.
  • Yusuke Ohba, Yoichiro Fujioka, Shigeyuki Nakada, Masumi Tsuda
    Progress in Molecular Biology and Translational Science 113 313 - 348 2013年 [査読有り][通常論文]
     
    Green fluorescent protein and its relatives have shed their light on a wide range of biological problems. To date, with a color palette consisting of fluorescent proteins with different spectra, researchers can "paint" living cells as they desire. Moreover, sophisticated biosensors engineered to contain single or multiple fluorescent proteins, including FRET-based biosensors, spatiotemporally unveil molecular mechanisms underlying physiological processes. Although such molecules have contributed considerably to basic research, their abilities to be used in applied life sciences have yet to be fully explored. Here, we review the molecular bases of fluorescent proteins and fluorescent protein-based biosensors and focus on approaches aimed at applying such proteins to the clinic. © 2013 Elsevier Inc.
  • Ryuta Arai, Masumi Tsuda, Takuya Watanabe, Toyoyuki Ose, Chikashi Obuse, Katsumi Maenaka, Akio Minami, Yusuke Ohba
    EUROPEAN JOURNAL OF CANCER 48 15 2417 - 2430 2012年10月 [査読有り][通常論文]
     
    Synovial sarcoma is an obstinate, high-grade malignancy because of its modest responses to radiotherapy and chemotherapy; the identification of effective therapeutics for this sarcoma is therefore necessary. Inhibition of Src family kinases (SFKs) suppresses the proliferation of synovial sarcoma cells in vitro, as we have previously reported. In this study, to validate the efficacy of Src inhibition in vivo, we employed SU6656, which was originally identified as a specific SFK inhibitor. SU6656 treatment significantly impaired the growth of established, existing tumours formed by synovial sarcoma cells in mice. Tumour cell invasion into the surrounding tissues was also abolished by SU6656. It is noteworthy that SU6656 but not PP2 induced a defect in cleavage furrow formation during cytokinesis, resulting in G2/M accumulation and subsequent apoptosis. Intriguingly, SU6656 abrogated the catalytic activities of Aurora kinases and led to the down-regulation of phosphorylated histone H3 coincidently with p53 accumulation, as did the Aurora kinase inhibitor VX-680. Structural comparison indicated an extensive similarity between the catalytic domains of SFKs and Aurora kinases. The structural analysis also revealed the potential binding mode of SU6656 to the ATP-binding cleft of Aurora B via four hydrogen bonds. SU6656 prevented angiogenesis within the tumours by attenuating vascular endothelial growth factor (VEGF) production by tumour cells and the subsequent chemotaxis of endothelial cells; these effects were the result of the inhibition of SFKs but not Aurora kinases. Based on these results, we hereby report a novel property of SU6656 as a dual inhibitor of SFKs and Aurora kinases, the suppression of both of which effectively abrogates tumour development and the progression of synovial sarcoma in vivo. (C) 2011 Elsevier Ltd. All rights reserved.
  • 大場雄介, 津田真寿美
    生化学 84 5 359 - 365 2012年05月25日 [査読無し][通常論文]
  • Yusuke Ohba, Masumi Tsuda
    Seikagaku 84 5 359 - 365 2012年 [査読有り][通常論文]
  • Masumi Tsuda, Shinya Tanaka
    Genes and Cancer 3 5-6 334 - 340 2012年 [査読有り][通常論文]
     
    The Crk family of adaptors is implicated in regulating various biological and pathological processes such as cell proliferation, adhesion, migration, invasion, phagocytosis, and survival. A large number of studies have shown that Crk plays an important role in aggressive and malignant behaviors of human cancers. In immunohistochemical analyses and gene-expression profiles, enhanced expression of Crk has been identified in adenocarcinomas of lung, breast, and stomach and in sarcomas and glioma. Overexpression of Crk in tumor cells induces the prominent tyrosine phosphorylations of scaffolding molecules such as p130Cas and paxillin through Src family tyrosine kinases and stimulates the activation loop of intracellular signalling, ultimately contributing to the increased motility and aggressive potential of cancer cells. Crk proteins thus are not simply conduits for intracellular signal transduction but also can control the amplitude of signalling. This review summarizes the significance of Crk and its mediated signaling assemblies, particularly in regulating tumor metastasis and invasion, and discusses the possibilities that they are potential cancer therapeutic targets. © The Author(s) 2012.
  • 近藤健, 金安顕子, 盛暁生, 入江達朗, 津田真寿美, 森岡正信, 今村雅寛, 大場雄介
    臨床血液 52 9 1133  2011年09月30日 [査読無し][通常論文]
  • Ohba Y, Tsuda M
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica 138 1 13 - 17 1 2011年07月 [査読有り][通常論文]
     
    下村脩博士によって,<I>Aequorea victoria</I> の発光器官から緑色蛍光タンパク質GFP(green fluorescent protein)が発見され,1992年にそのcDNAが単離されて以来,生細胞イメージングは生物学研究の必須ツールになっている.GFPはcDNAの細胞導入のみで,生理的環境下での目的タンパク質の局在や局在変化を可視化し,種々のカラーバリアントが入手可能な現在では複数のタンパク質の挙動の同時観察も可能である.また,フェルスター共鳴エネルギー移動(FRET: Förster resonance energy transfer)や蛍光タンパク質再構成法(BiFC: bimolecular fluorescence complementation)等の技術を用いることで,個々のタンパク質の局在や動態のみならずタンパク質の質的変化,つまりタンパク質間相互作用・構造変化等の時間的・空間的な変化の解析も可能である.これらの手法は細胞内シグナル伝達のダイナミクスを解析するために,最も適したツールと言っても過言ではない.本稿では,蛍光イメージングの基礎や応用例の紹介と各実験系が持つ得失を比較し,それぞれの実験系が何を可視化するのに適しているかを議論したい.
  • Tamaki Yamada, Masumi Tsuda, Tomomi Takahashi, Yasunori Totsuka, Masanobu Shindoh, Yusuke Ohba
    AMERICAN JOURNAL OF PATHOLOGY 178 6 2845 - 2856 2011年06月 [査読有り][通常論文]
     
    Recent findings have focused attention on the molecular consequences of the microenvironment in tumor progression, but events occurring in cancer cells themselves in response to their ambient conditions remain obscure. Here, we identify receptor activator of nuclear factor kappa B ligand (RANKL) as a microenvironment-specific factor essential for tumorigenesis in vivo, using head and neck squamous cell carcinoma (HNSCC) as a model. In human HNSCC tissues, RANKL is abundantly expressed, and its expression level correlates with the histological grade of differentiation. RANKL levels are significantly higher in poorly differentiated SCCs than in well or moderately differentiated SCCs. In contrast, all HNSCC cell lines tested displayed extremely low RANKL expression; however, RANKL is efficiently up-regulated when these cell lines are inoculated in the head and neck region of mice. RANKL expression is restored in a microenvironment-specific manner, and cannot be observed when the cells are inoculated in the hindlimbs. Forced expression of RANKL compensates for tumor growth in the hindlimb milieu, promotes epithelial mesenchymal transition, and induces tumor angiogenesis, in a manner independent of vascular endothelial growth factor (VEGF). These results implicate RANKL expression causatively in tumor growth and progression in HNSCC in vivo. RANKL may provide a novel functional marker for biological malignancy and a therapeutic target based on the specific nature of the microenvironment. (Am J Pathol 2011, 178:2845-2854. DOI: 10.1016/j.ajpath.2011.02.003)
  • Yoichiro Fujioka, Masumi Tsuda, Tomoe Hattori, Junko Sasaki, Takehiko Sasaki, Tadaaki Miyazaki, Yusuke Ohba
    PLOS ONE 6 1 e16324  2011年01月 [査読有り][通常論文]
     
    Background: Influenza virus infection causes highly contagious, severe respiratory disorders and gives rise to thousands of deaths every year; however, the efficacy of currently approved defense strategies, including vaccines and neuraminidase inhibitors, is limited because the virus frequently acquires resistance via antigen drift and reassortment. It is therefore important to establish a novel, effective therapeutic strategy that is effective irrespective of viral subtype. Methodology/Principal Findings: Here, we identify the Ras-phosphoinositide 3-kinase (PI3K) signaling pathway as a host-cell regulatory mechanism for influenza virus entry. The binding of Ras to PI3K is specifically involved in clathrinin-dependent endocytosis, endosomal maturation, and intracellular transport of viruses, which result in decreased infectious efficacy of different subtypes of influenza viruses in cells lacking the Ras-PI3K interaction. Moreover, influenza virus infection indeed triggered Ras activation and subsequent PI3K activation in early endosomes. Conclusions/Significance: Taken together, these results demonstrate that the Ras-PI3K signaling axis acts as a host-oriented mechanism for viral internalization. Given that virus incorporation is a process conserved among virus subtypes and species, this signaling pathway may provide a target for potent, well-tolerated prophylactics and therapeutics against a broad range of viruses.
  • Tatsuaki Mizutani, Takeshi Kondo, Stephanie Darmanin, Masumi Tsuda, Shinya Tanaka, Minoru Tobiume, Masahiro Asaka, Yusuke Ohba
    CLINICAL CANCER RESEARCH 16 15 3964 - 3975 2010年08月 [査読有り][通常論文]
     
    Purpose: To develop a novel diagnostic method for the assessment of drug efficacy in chronic myeloid leukemia (CML) patients individually, we generated a biosensor that enables the evaluation of BCR-ABL kinase activity in living cells using the principle of fluorescence resonance energy transfer (FRET). Experimental Design: To develop FRET-based biosensors, we used CrkL, the most characteristic substrate of BCR-ABL, and designed a protein in which CrkL is sandwiched between Venus, a variant of YFP, and enhanced cyan fluorescent protein, so that CrkL intramolecular binding of the SH2 domain to phosphorylated tyrosine (Y207) increases FRET efficiency. After evaluation of the properties of this biosensor by comparison with established methods including Western blotting and flow cytometry, BCR-ABL activity and its response to drugs were examined in CML patient cells. Results: After optimization, we obtained a biosensor that possesses higher sensitivity than that of established techniques with respect to measuring BCR-ABL activity and its suppression by imatinib. Thanks to its high sensitivity, this biosensor accurately gauges BCR-ABL activity in relatively small cell numbers and can also detect <1% minor drug-resistant populations within heterogeneous ones. We also noticed that this method enabled us to predict future onset of drug resistance as well as to monitor the disease status during imatinib therapy, using patient cells. Conclusion: In consideration of its quick and practical nature, this method is potentially a promising tool for the prediction of both current and future therapeutic responses in individual CML patients, which will be surely beneficial for both patients and clinicians. Clin Cancer Res; 16(15); 3964-75. (C) 2010 AACR.
  • Kaori Tsutsumi, Yoichiro Fujioka, Masumi Tsuda, Hideaki Kawaguchi, Yusuke Ohba
    CELLULAR SIGNALLING 21 11 1672 - 1679 2009年11月 [査読有り][通常論文]
     
    Recent studies indicate the importance of spatiotemporal regulation in the diversity and specificity of intracellular signaling. Here, we show that Ras-PI3K signaling plays an important role in the local regulation of phosphatidylinositol metabolism in the endosome through live-cell imaging by using a bimolecular fluorescence complementation technique, in which molecular interaction is indicated by fluorescence emission. Using several possible combinations of Ras and the Ras-binding domain, we identified an optimal set of probe molecules that yielded the most significant increase in fluorescence intensity between the active and inactive forms of Ras. This combination revealed that, among the Ras effectors tested, phosphatidy-linositol 3-kinase (PI3K) was specifically implicated in signaling in the endosome. We also found that full length PI3K was recruited to the endosome in EGF- and Ras-dependent manners, which appears to be essential for the activation of PI3K in this compartment. Taken together, these findings demonstrate that the spatiotemporal regulation of Ras-PI3K signaling may dictate the activation of PI3K and subsequent downstream signaling in the endosome. (C) 2009 Elsevier Inc. All rights reserved.
  • 津田 真寿美, 大場 雄介
    細胞 41 11 462 - 465 ニューサイエンス社 2009年10月 [査読無し][通常論文]
  • Takuya Watanabe, Masumi Tsuda, Shinya Tanaka, Yusuke Ohba, Hideaki Kawaguchi, Tokifumi Majima, Hirofumi Sawa, Akio Minami
    MOLECULAR CANCER RESEARCH 7 9 1582 - 1592 2009年09月 [査読有り][通常論文]
     
    The adaptor protein Crk mediates intracellular signaling related to cell motility and proliferation and is implicated in human tumorigenesis. The role of Crk in the growth of human sarcoma has remained unclear, however. The present study shows that Crk-induced activation of Src and subsequent signaling by p38 mitogen-activated protein kinase (MAPK) contribute to the enhanced proliferation of human synovial sarcoma cells. Depletion of Crk by RNA interference markedly inhibited proliferation of the synovial sarcoma cell lines HS-SYII, SYO-1, and Fuji as well as prevented anchorage-independent growth. Conversely, reconstitution with CrkII by authentic small interfering RNA-resistant Crk gene restored proliferation in Crk-silenced SYO-1 cells. Crk-depleted synovial sarcoma cells manifested enhanced transcriptional activity and expression of the p16(INK4A) gene, resulting in their accumulation in G, phase of the cell cycle. In response to hepatocyte growth factor stimulation, Crk prominently induced the tyrosine phosphorylation of Grb2-associated binder 1 through activation of Src and focal adhesion kinase, and the Src family kinase inhibitor PP2 almost completely inhibited the proliferation of SYO-1 cells. Crk also induced the phosphorylation of p38 MAPK, and SB203580, a p38 MAPK-specific inhibitor, increased expression of p16(INK4A) gene in SYO-1 cells. Furthermore, SB203580 or depletion of p38 MAPK by small interfering RNA suppressed both the phosphorylation of Akt triggered by hepatocyte growth factor and the proliferation of SYO-1 cells. These results suggest that Crk promotes proliferation of human synovial sarcoma cells through activation of Src and its downstream signaling by a novel p38 MAPK-Akt pathway, with these signaling molecules providing potent new targets for molecular therapeutics. (Mol Cancer Res 2009;7(9):1582-92)
  • Taichi Kimura, Mieko Sakai, Kouichi Tabu, Lei Wang, Ryosuke Tsunematsu, Masumi Tsuda, Hirofumi Sawa, Kazuo Nagashima, Hiroshi Nishihara, Shigetsugu Hatakeyama, Keiko Nakayama, Marc Ladanyi, Shinya Tanaka, Keiichi I. Nakayama
    LABORATORY INVESTIGATION 89 6 645 - 656 2009年06月 [査読有り][通常論文]
     
    SYT-SSX protein, resulted from chromosomal translocation, causes synovial sarcoma, which is a malignant tumor accounting for 10% of soft tissue sarcoma. However, biological functions of SYT (synovial sarcoma translocation), also known as SS18, are largely unclear, whereas it has been proven that Syt-null mice die at early stages of embryonic development. Here, we generated Syt-deficient mice and confirmed the reported phenotypes, including growth retardation, open neural tube and haplo-insufficient lethality, and therefore, there is no doubt that Syt is essential for embryonic development. However, placental defects, described in the earlier report, were rarely seen in our mice and we frequently observed cardiac defect in Syt-deficient mice. As the mechanisms responsible for embryonic lethality seem to be complicate, we performed additional experiments. By using primary cultured embryonic fibroblasts, we showed that Syt(-/-) MEFs deregulate actin organization and suppressed cell migration. These observations suggest that Syt may contribute to the signaling pathway important for various cellular functions in vivo and in vitro, and we propose that Syt-deficient MEFs would be a powerful means to understand the biological roles of SYT in vitro. Laboratory Investigation (2009) 89, 645-656; doi:10.1038/labinvest.2009.25; published online 30 March 2009
  • Takuya Watanabe, Masumi Tsuda, Yoshinori Makino, Tassos Konstantinou, Hiroshi Nishihara, Tokifumi Majima, Akio Minami, Stephan M. Feller, Shinya Tanaka
    CELL RESEARCH 19 5 638 - 650 2009年05月 [査読有り][通常論文]
     
    Upon growth factor stimulation, the scaffold protein, Gab1, is tyrosine phosphorylated and subsequently the adaptor protein, Crk, transmits signals from Gab1. We have previously shown that Crk overexpression, which is detectable in various human cancers, induces tyrosine phosphorylation of Gab1 without extracellular stimuli. In the present study, the underlying mechanisms were further investigated. Mutational analyses of CrkII demonstrated that the SH2 domain, but not the SH3(N) or the regulatory Y221 residue of CrkII, is critical for the induction of Gab1-Y307 phosphorylation. SH2 mutation of CrkII also decreased the interaction with Gab1. In GST pull-down assay, Crk-SH2 bound to wild-type Gab1, whereas Crk-SH3(N) interacted with the Gab1 mutant, which lacks the clustered tyrosine region (residues 242-410). Tyrosine phosphorylation of Gab1 was induced by all Crk family proteins, but not other SH2-containing signalling adaptors. Src-family kinase inhibitor, PP2, abrogates Crk-induced tyrosine phosphorylations of Gab1. Y307 phosphorylation was undetectable in fibroblasts lacking Src, Yes, and Fyn, even upon overexpression of Crk, whereas cells lacking only Yes and Fyn still contained Gab1 with phosphorylated Y307. Furthermore, Crk induced the phosphorylation of Src-Y416; accordingly the interaction between Crk and Csk was increased. The Gab1-Y307F mutant failed to localize near the plasma membrane even upon HGF stimulation and decreased cell migration. Moreover, Gab1-Y307F disturbed the localization of Crk, FAK, and paxillin, which are the typical components of focal adhesions. Taken together, these results indicate that Crk facilitates tyrosine phosphorylation of Gab1-Y307 through Src, contributing to the organization of focal adhesions and enhanced cell migration, thereby possibly promoting human cancer development.
  • Takayuki Inuzuka, Masumi Tsuda, Hideaki Kawaguchi, Yusuke Ohba
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 379 2 510 - 513 2009年02月 [査読有り][通常論文]
     
    We have recently reported that transcription factor 8 (TCF8) negatively regulates pathological angiogenesis by regulating endothelial invasiveness by acting as a transcriptional attenuator of matrix metalloproteinase 1. TCF8 also modulates cell-matrix and cell-cell adhesion; however molecular mechanism of this TCF8 function remains obscure. Here, we provide evidence that TCF8 activates R-Ras, another class of angiogenic regulator, to suppress angiogenesis by a mechanism other than a transcriptional attenuator. Tube formation by human umbilical vein endothelial cells (HUVECs) facilitated by TCF8 suppression was significantly inhibited by the expression of constitutive active mutant of R-Ras. When we examined the mRNA expression levels of R-Ras regulators, no significant changes were observed to explain the R-Ras activation by TCF8. Interestingly, we found that TCF8 bound to CalDAG-GEFIII, an R-Ras activator, in the cytosol, indicating that TCF8 emanates signaling for R-Ras activation from cytosol to regulate angiogenesis negatively. (C) 2008 Elsevier Inc. All rights reserved.
  • Takayuki Inuzuka, Masumi Tsuda, Shinya Tanaka, Hideaki Kawaguchi, Yujiro Higashi, Yusuke Ohba
    CANCER RESEARCH 69 4 1678 - 1684 2009年02月 [査読有り][通常論文]
     
    Angiogenesis is involved in various physiologic and pathological conditions, including tumor growth, and is tightly regulated by the orchestration of proangiogenic and antiangiogenic factors. Inhibition of vascular endothelial growth factor (VEGF), the best-established antiangiogenic treatment in cancer, has shown some effectiveness; however, the identification of novel regulators, whose function is independent of VEGF, is required to achieve better outcomes. Here, we show that transcription factor 8 (TCF8) is up-regulated in endothelial cells during angiogenesis, acting as a negative regulator. Furthermore, TCF8 is specifically expressed in the endothelium of tumor vessels. 1cf8-heterozygous knockout mice are more permissive than wildtype mice to the formation of tumor blood vessels in s.c. implanted melanoma, which seems to contribute to the more aggressive growth and the lung metastases of the tumor in mutant mice. Suppression of TCF8 facilitates angiogenesis in both in vitro and ex vivo models, and displays comprehensive cellular phenotypes, including enhanced cell invasion, impaired cell adhesion, and increased cell monolayer permeability due to, at least partly, MMPI overexpression, attenuation of focal adhesion formation, and insufficient VE-cadherin recruitment, respectively. Taken together, our findings define a novel, integral role for TCF8 in the regulation of pathologic angiogenesis, and propose TCF8 as a target for therapeutic intervention in cancer. [Cancer Res 2009;69(4):1678-84]
  • Kaori Tsutsumi, Masumi Tsuda, Natsuka Yazawa, Hirotaka Nakamura, Seiichiro Ishihara, Hisashi Haga, Motoaki Yasuda, Rie Yamazaki, Hiroki Shirato, Hideaki Kawaguchi, Takeshi Nishioka, Yusuke Ohba
    CELL STRUCTURE AND FUNCTION 34 2 89 - 96 2009年 [査読有り][通常論文]
     
    Radiotherapy is an important noninvasive treatment for many types of cancer. However, it has been reported that the proliferative, invasive, and metastatic capacities of tumor cells can be increased in the repopulated tumors that survive radiotherapy. We have previously established a radiation-surviving cell model for the human non-small cell lung cancer cell line H1299 by harvesting relic cells 14 days after irradiation (IR cells). Here, we report that cell invasion, cell migration, and cell adhesion are enhanced in these surviving cancer cells. The mRNA expression levels of matrix metalloproteinases (MMPs), including mmp1, mmp2, and mmp9, were upregulated in IR cells compared with parental cells. A gelatin zymogram, wound healing assay, and invasion assay showed increased MMP activity, cell motility, and invasiveness in IR cells, respectively. Moreover, IR cells adhered more tightly to collagen-coated dishes than parental cells. Consistently, paxillin, phosphorylated FAK, integrin beta 1, and vinculin were strongly localized at focal adhesions in IR cells, as visualized by immunofluorescence. In this report, we identify molecules responsible for the malignant properties of tumor cells that survive irradiation. These molecules may be important therapeutic targets for the control of repopulated tumors after radiotherapy.
  • 大場雄介, 津田真寿美
    実験医学 26 15 2506 - 2513 2008年09月15日 [査読無し][通常論文]
  • Xu Dong-mei, Linghu Hua, Masumi Tsuda, Shinya Tanaka, Kazuo Nagashima
    CHINESE JOURNAL OF CANCER RESEARCH 20 2 121 - 125 2008年06月 [査読有り][通常論文]
     
    Objective: The mucus production is an indicator for the histological grade of mucinous epithelial ovarian cancer (mEOC). In our previous study, Crk expression was targeted in the human ovarian mucinous adenocarcinoma cell line MCAS through RNA interference, resulting in the establishment of Crk knock down cells. These cells exhibited decreased tumorigenic potential both in vitro and in vivo. The purpose of this study was to investigate if there is any change in the capability of forming mucus in these Crk knock down cells. Methods: Cytoplasmic periodic acid Schiff (PAS) staining and particle excluding assay were conducted to assess the mucus formation within and around cells, respectively. Additionally, the amount of mucus formed in tumor lumps from nude mice model was measured following HE and PAS staining. Results: The increased mucus production in Crk knockdown mEOC cells (MCAS) was manifested by increased number of enlarged cells filled with vacuoles-like mucus observed by phase-contrast microscope and cytoplasmic PAS staining; and enhanced mucus secretion was represented by the assembly of pericellular matrix in particle excluding assay and increased mucus area in tumor lumps from nude mice models. Conclusion: The course of carcinogenesis in mEOC is associated with the altered pattern of mucus production and secretion. The adaptor protein Crk is implicated in both pathways.
  • Tamaki Yamada, Masumi Tsuda, Yusuke Ohba, Hideaki Kawaguchi, Yasunori Totsuka, Masanobu Shindoh
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 368 3 575 - 581 2008年04月 [査読有り][通常論文]
     
    Parathyroid hormone-related protein (PTHrP) is detected in many aggressive tumors and involved in malignant conversion; however, the underlying mechanism remains obscure. Here, we identified PTHrP as a mediator of epidermal growth factor receptor (EGFR) signaling to promote the malignancies of oral cancers. PTHrP mRNA was abundantly expressed in most of the quiescent oral cancer cells, and was significantly upregulated by EGF stimulation via ERK and p38 MAPK. PTHrP silencing by RNA interference, as well as EGFR inhibitor AG1478 treatment, significantly suppressed cell proliferation, migration, and invasiveness. Furthermore, combined treatment of AG1478 and PTHrP knockdown achieved synergistic inhibition of malignant phenotypes. Recombinant PTHrP substantially promoted cell motility, and rescued the inhibition by PTHrP knockdown, suggesting the paracrine/autocrine function of PTHrP. These data indicate that PTHrP contributes to the malignancy of oral cancers downstream of EGFR signaling, and may thus provide a therapeutic target for oral cancer. (c) 2008 Elsevier Inc. All rights reserved.
  • Lei Wang, Kouichi Tabu, Taichi Kimura, Masumi Tsuda, Hua Linghu, Mishie Tanino, Sadao Kaneko, Hiroshi Nishihara, Shinya Tanaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 362 4 976 - 981 2007年11月 [査読有り][通常論文]
     
    Signaling adaptor protein Crk has been shown to be involved in pathogenesis of human cancers including brain tumor where Crk was reported to be overexpressed. In this study, we addressed whether Crk is indispensable for malignant phenotype of brain tumor. In 20 surgical specimens of glioma, mRNA of both CrkI and CrkII was found to be elevated in malignant tumor. To define a precise role of Crk, we have established Crk-knockdown cell lines of glioblastoma KMG4 by siRNA, and early phase of cell adhesion to laminin was found to be suppressed. Wound healing assay revealed the decreased cell motility in Crk knockdown cells, and suppression of both anchorage-dependent and -independent growth were demonstrated in these cells. Furthermore, in vivo tumor forming potential was also markedly suppressed. These results suggest that Crk is required for early attachment to laminin, cell motility, and growth of glioblastoma cell line KMG4. (C) 2007 Elsevier Inc. All rights reserved.
  • 津田真寿美, 川口秀明
    癌の臨床 52 12 721 - 730 2007年06月20日 [査読無し][通常論文]
  • Masumi Tsuda, Ian J. Davis, Pedram Argani, Neerav Shukla, Gael G. McGill, Makoto Nagai, Tsuyoshi Saito, Marick Lae, David E. Fisher, Marc Ladanyi
    CANCER RESEARCH 67 3 919 - 929 2007年02月 [査読有り][通常論文]
     
    Specific chromosomal translocations encoding chimeric transcription factors are considered to play crucial oncogenic roles in a variety of human cancers but the fusion proteins themselves seldom represent suitable therapeutic targets. Oncogenic TFE3 fusion proteins define a subset of pediatric renal adenocarcinomas and one fusion (ASPL-TFE3) is also characteristic of alveolar soft part sarcoma (ASPS). By expression profiling, we identified the MET receptor tyrosine kinase gene as significantly overexpressed in ASPS relative to four other types of primitive sarcomas. We therefore examined MET as a direct transcriptional target of ASPL=TFE3. ASPL TFE3 binds to the MET promoter and strongly activates it. Likewise, PSF-TFE3 and NONO=TFE3 also bind this promoter. Induction of MET by ASPL-TFE3 results in strong MET autophosphorylation and activation of downstream signaling in the presence of hepatocyte growth factor (HGF). In cancer cell lines containing endogenous TFE3 fusion proteins, inhibiting MET by BNA interference or by the inhibitor PHA665752 abolishes HGF-dependent MET activation, causing decreased cell growth and loss of HGF-dependent phenotypes. MET is thus a potential therapeutic target in these cancers. Aberrant transcriptional up-regulation of MET by oncogenic TFE3 fusion proteins represents another mechanism by which certain cancers become dependent on MET signaling. The identification of kinase signaling pathways transcriptionally up-regulated by oncogenic fusion proteins may reveal more accessible therapeutic targets in this class of human cancers.
  • Takuya Watanabe, Masumi Tsuda, Yoshinori Makino, Shin Ichihara, Hirofumi Sawa, Akio Minami, Naoki Mochizuki, Kazuo Nagashima, Shinya Tanaka
    MOLECULAR CANCER RESEARCH 4 7 499 - 510 2006年07月 [査読有り][通常論文]
     
    Activation of the c-Met receptor tyrosine kinase through its ligand, hepatocyte growth factor (HGF), promotes mitogenic, motogenic, and morphogenic cellular responses. Aberrant HGF/c-Met signaling has been strongly implicated in tumor cell invasion and metastasis. Both HGF and its receptor c-Met have been shown to be overexpressed in human synovial sarcoma, which often metastasizes to the lung; however, little is known about HGF-mediated biological effects in this sarcoma. Here, we provide evidence that Crk adaptor protein is required for the sustained phosphorylation of c-Met-docking protein Grb2-associated binder 1 (Gab1) in response to HGF, leading to the enhanced cell motility of human synovial sarcoma cell lines SY0-1, HS-SY-II, and Fuji. HGF stimulation induced the sustained phosphorylation on Y307 of Gab1 where Crk was recruited. Crk knockdown by RNA interference disturbed this HGF-induced tyrosine phosphorylation of Gab1. By mutational analysis, we identified that Src homology 2 domain of Crk is indispensable for the induction of the phosphorylation on multiple Tyr-X-X-Pro motifs containing Y307 in Gab1. HGF remarkably stimulated cell motility and scattering of synovial sarcoma cell lines, consistent with the prominent activation of Rac1, extreme filopodia formation, and membrane ruffling. Importantly, the elimination of Crk in these cells induced the disorganization of actin cytoskeleton and complete abolishment of HGF-mediated Rac1 activation and cell motility. Time-lapse microscopic analysis revealed the significant attenuation in scattering of Crk knockdown cells following HGF treatment. Furthermore, the depletion of Crk remarkably inhibited the tumor formation and its invasive growth in vivo. These results suggest that the sustained phosphorylation of Gab1 through Crk in response to HGF contributes to the prominent activation of Rac1 leading to enhanced cell motility, scattering, and cell invasion, which may support the crucial role of Crk in the aggressiveness of human synovial sarcoma.
  • H Linghu, M Tsuda, Y Makino, M Sakai, T Watanabe, S Ichihara, H Sawa, K Nagashima, N Mochizuki, S Tanaka
    ONCOGENE 25 25 3547 - 3556 2006年06月 [査読無し][通常論文]
     
    Signaling adaptor protein Crk regulates cell motility and growth through its targets Dock180 and C3G, those are the guanine-nucleotide exchange factors (GEFs) for small GTPases Rac and Rap, respectively. Recently, overexpression of Crk has been reported in various human cancers. To de. ne the role for Crk in human cancer cells, Crk expression was targeted in the human ovarian cancer cell line MCAS through RNA interference, resulting in the establishment of three Crk knockdown cell lines. These cell lines exhibited disorganized actin fibers, reduced number of focal adhesions, and abolishment of lamellipodia formation. Decreased Rac activity was demonstrated by pull-down assay and FRET-based time-lapse microscopy, in association with suppression of both motility and invasion by phagokinetic track assay and transwell assay in these cells. Furthermore, Crk knockdown cells exhibited slow growth rates in culture and suppressed anchorage-dependent growth in soft agar. Tumor forming potential in nude mice was attenuated, and intraperitoneal dissemination was not observed when Crk knockdown cells were injected into the peritoneal cavity. These results suggest that the Crk is a key component of focal adhesion and involved in cell growth, invasion, and dissemination of human ovarian cancer cell line MCAS.
  • K Tabu, A Ohnishi, Y Sunden, T Suzuki, M Tsuda, S Tanaka, T Sakai, K Nagashima, H Sawa
    JOURNAL OF CELL SCIENCE 119 7 1433 - 1441 2006年04月 [査読有り][通常論文]
     
    The basic helix-loop-helix transcription factor OLIG2 is specifically expressed in cells of the oligodendrocyte lineage. It is also expressed in various tumors originating from glial cells; however, the expression of OLIG2 is rare or weak in glioblastomas, the most malignant gliomas. The role of OLIG2 in glioma remains unclear. To investigate the function of OLIG2 in glial tumor cells, we have established a glioblastoma cell line, U12-1, in which the expression of OLIG2 is induced by the Tet-off system. Induction of OLIG2 resulted in suppression of both the proliferation and anchorage-independent growth of U12-1. It also resulted in an increase in the expression of p27(Kip1). A luciferase assay revealed that the CTF site of the p27(Kip1) gene promoter was essential for OLIG2-dependent activation of p27(Kip1) gene transcription. Electrophoretic mobility shift assays confirmed that a nuclear extract of OLIG2-expressing U12-1 cells contained a protein complex that binds to the CTF site of the p27(Kip1) gene promoter. Furthermore, siRNA against p27(Kip1) rescued the OLIG2-mediated growth and DNA synthesis inhibition of U12-1 cells. These results indicate that OLIG2 suppresses the proliferation of U12-1 and that this effect is mediated by transactivation of the p27(Kip1) gene, and low expression of OLIG2 may be related to the malignant behavior of human glioblastoma.
  • Y Makino, M Tsuda, S Ichihara, T Watanabe, M Sakai, H Sawa, K Nagashima, S Hatakeyama, S Tanaka
    JOURNAL OF CELL SCIENCE 119 5 923 - 932 2006年03月 [査読有り][通常論文]
     
    Dock180, a member of the CDM family of proteins, plays roles in biological processes such as phagocytosis and motility through its association with the signalling adaptor protein Crk. Recently, the complex formation between Dock180 and Elmo1 was reported to function as a bipartite guanine nucleotide exchange factor for Rac. In this study, we demonstrated that the amount of Dock180 increased when Elmo1 was co-expressed. Dock180 was found to be ubiquitylated and Dock180 protein levels could be augmented by treatment with proteasome inhibitor. The ubiquitylation of Dock180 was enhanced by epidermal growth factor (EGF), Crk and adhesion-dependent signals. Furthermore, Elmo1 inhibited labiquitylation of Dock180, resulting in the increase in Dock180 levels. The Elmo1 mutant Delta 531, which encompasses amino acids required for Dock180 binding, preserved the inhibitory effects on ubiquitylation of Dock180. Upon EGF stimulation, both Dock180 and ubiquitin were demonstrated to translocate to the cell periphery by immunofluorescence, and we found ubiquitylation of Dock180 and its inhibition by Elmo1 to occur in cellular membrane fractions by in vivo ubiquitylation assay. These data suggest that Dock180 is ubiquitylated on the plasma membrane, and also that Elmo1 functions as an inhibitor of ubiquitylation of Dock180. Therefore, an ubiquitin-proteasome-dependent protein degradation mechanism might contribute to the local activation of Rac on the plasma membrane.
  • 津田 真寿美, 川口 秀明
    癌の臨床 52 12 721 - 730 篠原出版新社 2006年 [査読無し][通常論文]
  • M Tsuda, T Watanabe, T Seki, T Kimura, H Sawa, A Minami, T Akagi, K Isobe, K Nagashima, S Tanaka
    ONCOGENE 24 54 7984 - 7990 2005年12月 [査読有り][通常論文]
     
    Oncogenic protein provokes cell cycle arrest termed premature senescence. In this process Ras has been known to induce cyclin-dependent kinase inhibitor (CKI) p16(INK4A) in primary fibroblasts. Here, we present a novel finding that human chimeric oncoprotein SYT-SSX1 induces CKI p21(WAF1/CIP1) (p21) for suppression of cell growth. In human synovial sarcoma cell lines, the expression levels of p21 were high and the transcriptional activity of the p21 gene promoter was significantly elevated. The transient expression of SYT- SSX1-induced activation of the p21 gene promoter in human diploid fibroblasts. The N-terminus deletion form of SYT-SSX1, which failed to bind to hBRM one of the chromatin remodeling factors, preserved the p21 induction ability. This effect of SYT-SSX1 was similar in extent in both wild-type and p53-deficient HCT116 cell lines. Furthermore, the introduction of mutation in Sp1/Sp3 binding sites of the p21 gene promoter abolished the SYT-SSX1-induced transcriptional activity of its promoter. In SW13 cells, the stable expression of SYT-SSX1 suppressed cell growth in culture. These results suggest that SYT-SSX1 is able to induce p21 in a manner independent on hBRM and p53 but dependent on Sp1/Sp3.
  • M Tsuda, Y Makino, T Iwahara, H Nishihara, H Sawa, K Nagashima, H Hanafusa, S Tanaka
    JOURNAL OF BIOLOGICAL CHEMISTRY 279 45 46843 - 46850 2004年11月 [査読有り][通常論文]
     
    Cell migration is a well organized process regulated by the extracellular matrix-mediated cytoskeletal reorganization. The signaling adaptor protein Crk has been shown to regulate cell motility, but its precise role is still under investigation. Herein, we report that Crk associates with ERM family proteins ( including ezrin, radixin, and moesin), activates RhoA, and promotes cell motility toward hyaluronic acid. The binding of Crk with ERMs was demonstrated both by transient and stable protein expression systems in 293T cells and 3Y1 cells, and it was shown that v-Crk translocated the phosphorylated form of ERMs to microvilli in 3Y1 cells by immunofluorescence and immunoelectron microscopy. This v-Crk-dependent formation of microvilli was suppressed by inhibitors of Rho-associated kinase, and the activity of RhoA was elevated by coexpression of c-Crk-II and ERMs in 3Y1 cells. In concert with the activation of RhoA by Crk, Crk was found to associate with Rho-GDI, which has been shown to bind to ERMs. Furthermore, upon hyaluronic acid treatment, coexpression of c-Crk-II and ERMs enhanced cell motility, whereas the sole expression of c-Crk-II or either of the ERMs decreased the motility of 3Y1 cells. These results suggest that Crk may be involved in regulation of cell motility by a hyaluronic acid-dependent mechanism through an association with ERMs.
  • QM Qu, H Sawa, T Suzuki, S Semba, C Henmi, Y Okada, M Tsuda, S Tanaka, WJ Atwood, K Nagashima
    JOURNAL OF BIOLOGICAL CHEMISTRY 279 26 27735 - 27742 2004年06月 [査読有り][通常論文]
     
    JC virus (JCV) belongs to the polyomavirus family of double-stranded DNA viruses and causes progressive multifocal leukoencephalopathy in humans. Although transport of virions to the nucleus is an important step in JCV infection, the mechanism of this process has remained unclear. The outer shell of the JCV virion comprises the major capsid protein VP1, which possesses a putative nuclear localization signal (NLS), and virus-like particles (VLPs) consisting of recombinant VP1 exhibit a virion-like structure and physiological functions ( cellular attachment and intracytoplasmic trafficking) similar to those of JCV virions. We have now investigated the mechanism of nuclear transport of JCV with the use of VLPs. Wild-type VLPs (wtVLPs) entered the nucleus of most HeLa or SVG cells. The virion structure of VLPs was preserved during transport to the nucleus as revealed by confocal microscopy of cells inoculated with fluorescein isothiocyanate-labeled wtVLPs containing packaged Cy3. The nuclear transport of wtVLPs in digitonin-permeabilized cells was dependent on the addition of importins alpha and beta and was prevented by wheat germ agglutinin or by antibodies to the nuclear pore complex. The nuclear entry of VLPs composed of VP1 with a mutated NLS was greatly inhibited, compared with that of wtVLPs, in both intact and permeabilized cells. Unlike wtVLPs, the mutant VLPs did not bind to importins alpha or beta. Limited proteolysis analysis revealed that the NLS of VP1 was exposed on the surface of wtVLPs. These results suggest that JCV VLPs bind to cellular importins via the NLS of VP1 and are transported into the nucleus through the nuclear pore complex.
  • A Ohnishi, H Sawa, M Tsuda, Y Sawamura, T Itoh, Y Iwasaki, K Nagashima
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 62 10 1052 - 1059 2003年10月 [査読有り][通常論文]
     
    Because a specific group of oligodendrogliomas is susceptible to adjuvant therapy, it is important to elucidate the biological characteristics of these tumors. In situ hybridization analyses have revealed that Olig genes are expressed in oligodendroglial lineage cells and are highly expressed in oligodendrogliomas. To clarify whether OLIG is a tumor-specific marker for oligodendrogliomas, we have investigated the expression of Olig transcripts by semiquantitative RT-PCR assay and OLIG2 protein with a new antibody in a variety of glial tumors. The semiquantitative RT-PCR revealed that high levels of expression of Olig1 and Olig2 mRNAs were present in anaplastic oligodendrogliomas and anaplastic astrocytomas, while expression of these mRNAs in grade IV glioblastomas was lower than in grade II and grade III gliomas (p < 0.01). Immunohistochemical analyses demonstrated that the mean immunopositive proportion of OLIG2 was 82% in anaplastic oligodendrogliomas but only 34% in anaplastic astrocytomas. Therefore, although OLIG2 expression was detected in a range of gliomas not specific for oligodendrogliomas, the expression level in anaplastic oligodendrogliomas was more uniform and intense than that in other glial tumors. In conclusion, combining Olig mRNA expression and immunohistochemistry of OLIG2 enables oligodendrogliomas to be distinguished from glioblastomas and other astrocytic glial tumors.
  • 田中伸哉, 津田真寿美, 平賀博明, 三浪明男, 長嶋和郎
    病理と臨床 21 6 593 - 603 2003年06月01日 [査読無し][通常論文]
  • AE Salah-Eldin, S Inoue, SE Tsukamoto, H Aoi, M Tsuda
    INTERNATIONAL JOURNAL OF CANCER 103 1 53 - 60 2003年01月 [査読有り][通常論文]
     
    Apoptosis is induced by many kinds of therapy-related inducers, such as hyperthermia and chemotherapeutic agents. However, differences in apoptotic pathways between these inducers remain unclear, although knowing the differences is important to map out a therapeutic strategy. Therefore, we focused on the localization and phosphorylation of Bcl-2 and Bax, key mediators of the apoptotic pathway, after hyperthermia and paclitaxel treatment of PC-10 squamous cell carcinoma cells that excessively expressed Bcl-2 and Bax in the cytoplasm. Paclitaxel treatment markedly induced qualitative changes in Bcl-2, whereas hyperthermia did only quantitative changes in Bax. The levels of Bax increased gradually with the duration of hyperthermia, whereas Bcl-2 levels slightly decreased. On the other hand, paclitaxel treatment induced dose- and time-dependent phosphorylation of Bcl-2. Interestingly, phosphorylated Bcl-2 was observed in the specific subcellular sites, mitochondria- and lysosome-rich fractions. Both treatments disturbed the heterodimerization of Bax with Bcl-2. Hyperthermia, but not paclitaxel treatment, induced a gradual Bax translocation from the cytoplasm to the nucleus. Although both treatments induced a prominent cell cycle disturbance in the G(2)M phase, paclitaxel treatment induced typical apoptosis, and hyperthermia hardly induced apoptosis. Our results suggest that the subcellular redistribution of Bax and the phosphorylation of Bcl-2 depend on the type of apoptosis inducers, such as hyperthermia and paclitaxel, and Bcl-2 has a central role in the decision of apoptotic outcome. Our data may afford new insights in apoptosis from the aspect of an association of Bcl-2 phosphorylation with intracellular Bax localization. (C) 2002 Wiley-Liss, Inc.
  • H Nishihara, M Maeda, A Oda, M Tsuda, H Sawa, K Nagashima, S Tanaka
    BLOOD 100 12 3968 - 3974 2002年12月 [査読有り][通常論文]
     
    The CDM (ced-5 of Caenorhabditis elegans, DOCK180 [downstream of Crk with molecular weight of 180 kDa] of humans, and myoblast city of Drosophila melanogaster) family of proteins has been shown to play a pivotal role in the integrin-mediated signaling pathway under the regulation of an adaptor molecule c-CT10- related kinase II (c-Crk-II) in adherent cells. Recently, hematopoietic cell-specific CDM protein DOCK2 has been shown to be indispensable for lymphocyte migration. However, the regulatory mechanism for DOCK2 is still unknown because DOCK2 lacks a c-Crk-II binding consensus motif. In this study, we demonstrated that DOCK2 bound to CrkL, which is present exclusively in hematopoietic cells both in vivo and in vitro, and we also found that 2 separate regions of DOCK2 contributed to its binding to Src homology 3 (SH3) domain of CrkL. Colocalization of DOCK2 with Crk-like (CrkL) and F-actin was shown by immunocytochemical analysis with the use of Jurkat cells. We also found that CrkL-induced activation of small guanine triphosphatase (GTPase) Rac1 was significantly inhibited by the DOCK2-dCS mutant in 293T cells. Furthermore, the association of DOCK2 and Vav, the guanine-nucleotide exchanging factor (GEF) for Rac1, was demonstrated in Jurkat cells. Finally, the stable expression of DOCK2-dCS mutant in Jurkat cells was shown to reduce cell attachment. These data suggest the presence of a novel protein complex of CrkL, DOCK2, and Vav to regulate Rac1 in leukemia cell lines. (C) 2002 by The American Society of Hematology.
  • H Nishihara, M Maeda, M Tsuda, Y Makino, H Sawa, K Nagashima, S Tanaka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 296 3 716 - 720 2002年08月 [査読有り][通常論文]
     
    DOCK2, a CDM family protein exclusively found in hematopoietic cells, has been shown to play a role in lymphocyte migration by the regulation of actin cytoskeleton. Although DOCK2 has been shown to induce the activation of Rac1, the regulatory mechanism of Rac2, which is a hematopoietic cell-specific small GTPase, is still unknown. In this study, we examined the role of DOCK2 in the activation of Rac2 in hematopoietic cells. DOCK2 was found to associate with the zeta subunit of the CD3 complex of T cell receptors in Jurkat cells and to activate forced expressed Rac2 in 293T cells. In addition, the stable expression of DOCK2 in Jurkat cells exhibited the elevated activity of endogenous Rac2. Furthermore, the transcriptional activity of interleukin-2 (IL-2) was enhanced in DOCK2-expressing Jurkat cells and the dominant negative form of Rac2 suppressed its elevated IL-2 promoter activity. These results suggest that DOCK2 mediates TCR-dependent activation of Rac2, leading to the regulation of IL-2 promoter activity in T cells. (C) 2002 Elsevier Science (USA). All rights reserved.
  • H Nishihara, S Tanaka, M Tsuda, S Oikawa, M Maeda, M Shimizu, H Shinomiya, A Tanigami, H Sawa, K Nagashima
    CANCER LETTERS 180 1 55 - 61 2002年06月 [査読有り][通常論文]
     
    Crk is a signaling adaptor protein which is mostly composed of SH2 and SH3 domains. and has been shown to play a pivotal role in cell proliferation. differentiation, and migration. Because Crk was originally isolated as an avian sarcoma virus CT10 encoding oncoprotein v-Crk. we examined a potential role for c-Crk in the carcinogenesis of human cancers. First, to analyze gene mutations of c-Crk, we isolated a human bacterial artificial chromosome clone containing Crk genome and exon/intron structures, However, polymerase chain reaction-single strand conformation polymorphism methods failed to show any genomic mutations in the Crk exon which could be related to carcinogenesis. Second, immunohistochemical analysis of c-Crk-II demonstrated that the levels of c-Crk-II were significantly elevated in most of the tumors, particularly in the colon and lung cancers. Furthermore, immunoblot analysis using human lung cancer cell lines revealed that the expression levels of c-Crk-II were correlated to growth rates of L cells. The elevated expression levels of c-Crk-II might be related to the development of human cancers. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
  • M Tsuda, S Tanaka, H Sawa, H Hanafusa, K Nagashima
    CELL GROWTH & DIFFERENTIATION 13 3 131 - 139 2002年03月 [査読有り][通常論文]
     
    The adaptor protein Crk has been reported to associate with focal adhesions and is thought to be involved in integrin-mediated signaling pathway. However, the precise mechanism of Crk-dependent regulation of cytoskeleton still remains under investigation. In this study, we have established a v-Crk-inducible cell line in rat fibroblasts 3Y1 cells and found that v-Crk activated Rho and induced actin stress fiber formation. In addition to the induction of tyrosine-phosphorylation of p130(Cas) and paxillin, we demonstrated that v-Crk induced threonine-phosphorylated bands sized at 72/78 kDa found specifically in 3Y1 cells. Both of the inhibitors of Rho and Rho-associated kinase, C3 and Y27632, respectively, inhibited these v-Crk-induced biochemical effects. Although v-Crk-induced cells exhibited a decrease of cell motility, integrin stimulation recovered the suppression of motility. Furthermore, v-Crk enhanced motility in chemotactic assay toward fibronectin with additional activation of Rho and the increase of levels of CD44 cleavage. These results suggest that v-Crk activated Rho and induced actin stress fiber formation and CD44 cleavage leading to the regulation of cell motility.
  • Nagai, M, Tanaka, S, Tsuda, M, Endo, S, Kato, H, Sonobe, H, Minami , A, Hiraga, H, Yamawaki, S, Nishihara, H, Sawa, H, Nagashima, K
    Proc.Natl.Acad.Sci.USA 98 7 3843 - 3848 2001年 [査読無し][通常論文]
  • A Salah-eldin, S Inoue, M Tsuda, A Matsuura
    JAPANESE JOURNAL OF CANCER RESEARCH 91 12 1269 - 1277 2000年12月 [査読有り][通常論文]
     
    Proapoptotic Bax is a member of the Bcl-2 family proteins, which have a key role in regulating programmed cell death. The intracellular localization and redistribution of Bax are important in promoting apoptosis. Bax contains a BH3 domain heterodimerizing with Bcl-2 and a hydrophobic transmembrane segment to be inserted in specified organelle membranes. In this study, Bcl-2 showed cytoplasmic localization in all of ten human lung cancer cell lines tested. Interestingly, Bax was localized in the nucleus in 7 cell lines, although Bax lacks nuclear import signals. This may allow cancer cells to escape from apoptosis. Why pax is able to exist in the nucleus is still unclear. We hypothesized that mutation in the BH3 domain and/or transmembrane segment of Bax possibly causes intracellular Bax distribution. We analyzed the sequence of the bax gene in these cell lines and found only a silent point mutation at codon 184 (TCG-->TCA) in the transmembrane segment in all cell lines. This finding indicates that changes in cellular localization of Bax in lung cancer cell lines do not depend on bax mutation and that Bax is possibly translocated into the nucleus without any mutation. This is the first report showing that Bax with the normal amino acid sequence can be localized in the nucleus in established lung cancer cell lines without any treatment of the cells.
  • 井上勝一, 飯塚雅由, 亀山雅世, 津田真寿美
    細胞 32 5 186 - 191 2000年05月20日 [査読無し][通常論文]
  • Michiru Nishita, Shoichi Inoue, Masumi Tsuda, Chie Tateda, Toshiyuki Miyashita
    Experimental Cell Research 244 1 357 - 366 1998年10月10日 [査読有り][通常論文]
     
    Effects of hyperthermia at 42.5°C for 6 h on cell survival, cell cycle progression, and the localization and expression levels of Bcl-2 and Bax, as well as the association between Bcl-2 and Bax in human lung cancer cells were investigated. Untreated human lung cancer cells, though immortalized, expressed Bax unlike peripheral lymphocytes with low Bax expression. Bcl-2 was localized only in the cytoplasm in all the cell lines tested, whereas Bax was localized in the cytoplasm and/or nucleus (1) only in the nucleus in three cell lines, (2) either in the nucleus or the cytoplasm in three cell lines, (3) in both the nucleus and the cytoplasm in one cell line, and (4) only in the cytoplasm in three cell lines. Of 10 cell lines examined, 6 had a low sensitivity to hyperthermia with a viability of 50% or more, and four cell lines had a high sensitivity to hyperthermia with a viability of less than 50% regardless of cell type. In cell lines highly sensitive to hyperthermia, Bax was localized in the nucleus. Hyperthermia increased the cellular level of Bax, but not Bcl-2, and reduced the association between Bcl-2 and Bax expression in PC-10 cells. Although the Bax level increased, hyperthermia induced only mild apoptosis and caused prominent cell cycle disturbance, especially in the S and G2M phases. Thus, hyperthermia at 42.5°C for 6 h had cytostatic effect as well as caused mild apoptosis. Interestingly, during 3 h of hyperthermia, Bax translocated from the cytoplasm to the nucleus, whereas Bcl-2 remained in the cytoplasm. These results raise the possibility that Bax may lose its function as the inducer of apoptosis by translocating into the nucleus or have an unknown role in the nucleus.
  • 井上勝一, 津田真寿美, 飯塚雅由
    臨床検査 41 10 1123 - 1130 1997年10月 [査読無し][通常論文]
  • 岩崎正幸, 津田真寿美, 谷沢徹, 神山隆一
    臨床検査 41 8 959 - 962 1997年08月 [査読無し][通常論文]

MISC

  • 低分化胃癌におけるSox10発現の臨床病理学的検討
    石川 麻倫, 西原 広史, 林 秀幸, 木村 太一, 石田 雄介, 王 磊, 津田 真寿美, 谷野 美智枝, 坂本 直哉, 田中 伸哉 日本消化器病学会雑誌 115 (臨増総会) A375 -A375 2018年03月 [査読無し][通常論文]
  • アダプター分子CRKはエクソソームのErbB2を制御し、膀胱癌の増殖・転移を亢進する
    津田 真寿美, 吉田 一彦, 松本 隆児, 近藤 恒徳, 篠原 信雄, 田中 伸哉 日本癌学会総会記事 76回 E -1059 2017年09月 [査読無し][通常論文]
  • miR-23aによる膠芽腫の浸潤能亢進分子メカニズムの解明
    津田 真寿美, 谷地 一博, 高阪 真路, 三浪 友輔, 王 磊, 木村 太一, 谷野 美智枝, 西原 広史, 田中 伸哉 Brain Tumor Pathology 34 (Suppl.) 093 -093 2017年05月 [査読無し][通常論文]
  • グリオーマの日常診断におけるintegrated diagnosisの現状
    谷野 美智枝, 谷川 聖, 石田 雄介, 木村 太一, 岡田 佳奈子, 佐藤 真実, 津田 真寿美, 西原 広史, 長嶋 和郎, 田中 伸哉 Brain Tumor Pathology 34 (Suppl.) 102 -102 2017年05月 [査読無し][通常論文]
  • 大場雄介, 山田珠希, 山田珠希, 山田珠希, 津田真寿美, 藤岡容一朗, 藤岡真理, 堀内浩水, 堀口美香, 佐藤絢, ネパール ブラバ, 王せい, 柏木彩花, 西出真也, 南保明日香, 芳賀永, 田中伸哉, 進藤正信 日本生理学雑誌(Web) 79 (2) 49 (WEB ONLY) -49 2017年05月 [査読無し][通常論文]
  • 髄膜腫におけるPOLR2A遺伝子変異の検討
    鈴木 佑季, 津田 真寿美, 湯澤 明夏, 木村 太一, 石田 雄介, 谷野 美智枝, 西原 広史, 田中 伸哉 日本病理学会会誌 106 (1) 508 -508 2017年03月 [査読無し][通常論文]
  • 髄膜発生孤在性線維性腫瘍/血管周皮腫(SFT/HPC)におけるNAB2-STAT6融合遺伝子の解析
    四宮 万里絵, 津田 真寿美, 湯澤 明夏, 木村 太一, 石田 雄介, 谷野 美智枝, 西原 広史, 田中 伸哉 日本病理学会会誌 106 (1) 508 -509 2017年03月 [査読無し][通常論文]
  • 浸潤性膀胱癌の転移および薬剤耐性獲得におけるAKR1C1の役割
    津田 真寿美, 松本 隆児, 吉田 一彦, 谷野 美智枝, 木村 太一, 西原 広史, 阿部 崇重, 篠原 信雄, 野々村 克也, 田中 伸哉 日本病理学会会誌 106 (1) 340 -340 2017年03月 [査読無し][通常論文]
  • 仙葉愼吾, 後藤佳子, 北村信人, 北村信人, 黒野定, 近江谷克裕, 津田真寿美, 津田真寿美, 黒川孝幸, 黒川孝幸, 田中伸哉, 田中伸哉, GONG Jian Ping, GONG Jian Ping, 安田和則 再生医療 16 267 2017年02月01日 [査読無し][通常論文]
  • 吉田一彦, 吉田一彦, 谷野美智枝, 堀井理絵, 木村太一, 津田真寿美, 近藤恒徳, 秋山太, 畠山鎮次, 田邉一成, 田中伸哉 日本泌尿器科学会東部総会プログラム・抄録集 82nd 222 2017年 [査読無し][通常論文]
  • チロシンキナーゼ阻害剤耐性膠芽腫細胞における腫瘍幹細胞性獲得とSFRP1の関連性
    鈴鹿 淳, 津田 真寿美, 王 磊, 谷野 美智枝, 木村 太一, 西原 広史, 田中 伸哉 日本癌学会総会記事 75回 J -2036 2016年10月 [査読無し][通常論文]
  • 肺癌においてアダプター蛋白CrkはTGF-βシグナルと協調してEMTを誘導する
    谷野 美智枝, Elimansuri Aiman, Mahabir Roshan, 王 磊, 木村 太一, 西原 広史, 津田 真寿美, 田中 伸哉 日本癌学会総会記事 75回 P -1092 2016年10月 [査読無し][通常論文]
  • AKR1C1は膀胱癌の浸潤・転移と薬剤耐性を制御する
    津田 真寿美, 松本 隆児, 吉田 一彦, 谷野 美智枝, 木村 太一, 西原 広史, 阿部 崇重, 篠原 信雄, 野々村 克也, 田中 伸哉 日本癌学会総会記事 75回 E -1057 2016年10月 [査読無し][通常論文]
  • 多形黄色星細胞腫におけるBRAFV600Eの遺伝子変異とリン酸化ERK及びp16の発現の検討
    谷野 美智枝, 津田 真寿美, 石田 雄介, 木村 太一, 西原 広史, 長嶋 和郎, 田中 伸哉 日本病理学会会誌 105 (2) 75 -75 2016年09月 [査読無し][通常論文]
  • 脳腫瘍術中迅速病理診断における迅速免疫染色装置(ラピート)の使用経験
    森谷 純, 谷野 美智枝, 木村 太一, 石田 雄介, 津田 真寿美, 西原 広史, 田中 伸哉 日本病理学会会誌 105 (2) 76 -76 2016年09月 [査読無し][通常論文]
  • Synthetic PAMPS gel functions as protein reservoir, which induces a chondrogenic differentiation of chondrocytic ATDC5 cells(和訳中)
    仙葉 愼吾, 後藤 佳子, 北村 信人, 黒野 定, 近江谷 克裕, 津田 真寿美, 黒川 孝幸, グン・チェンピン, 田中 伸哉, 安田 和則 日本生化学会大会プログラム・講演要旨集 89回 [1T18 -05(1P 2016年09月 [査読無し][通常論文]
  • 髄膜発生SFT/HPCのNAB2-STAT6融合遺伝子パターンと臨床病理学的検討
    湯澤 明夏, 西原 広史, 王 磊, 津田 真寿美, 木村 太一, 谷野 美智枝, 田中 伸哉 Brain Tumor Pathology 33 (Suppl.) 102 -102 2016年05月 [査読無し][通常論文]
  • 臨床的シークエンス分析による髄膜腫の予後的影響(Prognostic impact for meningioma by clinical sequence system)
    湯澤 明夏, 西原 広史, 山口 秀, 毛利 普美, 王 磊, 木村 太一, 津田 真寿美, 谷野 美智枝, 佐藤 典宏, 田中 伸哉 日本病理学会会誌 105 (1) 356 -356 2016年04月 [査読無し][通常論文]
  • CRKアダプター蛋白質はHGF/c-Metフィードバックループを介して膀胱癌のEMTと転移を誘導する
    王 磊, 松本 隆児, 津田 真寿美, 間石 奈湖, 安部 崇重, 木村 太一, 谷野 美智枝, 西原 広史, 樋田 京子, 大場 雄介, 篠原 信雄, 田中 伸哉 日本癌学会総会記事 74回 J -1142 2015年10月 [査読無し][通常論文]
  • 膀胱癌転移巣におけるAldo-keto reductase(AKR)1C1の発現亢進は浸潤能と抗癌剤耐性能を反映する
    松本 隆児, 津田 真寿美, 安部 崇重, 篠原 信雄, 田中 伸哉, 野々村 克也 日本泌尿器科学会総会 103回 471 -471 2015年04月 [査読無し][通常論文]
  • 迅速免疫組織化学染色を用いた膠腫におけるIDH1染色の術中応用
    廣嶋 優子, 南條 博, 前田 大地, 後藤 明輝, 笹嶋 寿郎, 清水 宏明, 南谷 佳弘, 津田 真寿美, 田中 伸哉 日本病理学会会誌 104 (1) 296 -296 2015年03月 [査読無し][通常論文]
  • インフルエンザウイルスのCa2+シグナルを介した宿主細胞侵入機構
    藤岡 容一朗, 津田 真寿美, 南保 明日香, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 宮崎 忠昭, 大場 雄介 日本細胞生物学会大会講演要旨集 66回 103 -103 2014年05月 [査読無し][通常論文]
  • インフルエンザウイルスのCa2+シグナルを介した宿主細胞侵入機構
    藤岡 容一朗, 津田 真寿美, 南保 明日香, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 宮崎 忠昭, 大場 雄介 日本細胞生物学会大会講演要旨集 66回 146 -146 2014年05月 [査読無し][通常論文]
  • 大腸癌浸潤・転移におけるchorionic gonadotropin-βの機能解析とその臨床応用
    川俣 太, 本間 重紀, 西原 広史, 長津 明久, 旭 よう, 蒲池 浩文, 高橋 典彦, 津田 真寿美, 田中 伸哉, 神山 俊哉, 武冨 紹信 日本大腸肛門病学会雑誌 67 (3) 240 -240 2014年03月 [査読無し][通常論文]
  • Ras-PI3Kシグナルが制御する外来因子取込み機構の解析
    藤岡 容一朗, 津田 真寿美, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 宮崎 忠昭, 大場 雄介 日本生理学雑誌 76 (2) 81 -81 2014年03月 [査読無し][通常論文]
  • Roshan Mahabir, Mishie Tanino, Aiman Elmansuri, Masumi Tsuda, Taichi Kimura, Lei Wang, Hiroshi Nishihara, Shinya Tanaka MOLECULAR CANCER THERAPEUTICS 12 (11) 2013年11月 [査読無し][通常論文]
  • 消化器癌におけるERC/Mesothelinの分子病理学的検討(Molecular and clinicopathological analysis for ERC/Mesothelin in digestive cancers)
    西原 広史, 川俣 太, 永生 高広, 津田 真寿美, 王 磊, 樋野 興夫, 武冨 紹信, 田中 伸哉 日本癌学会総会記事 72回 308 -308 2013年10月 [査読無し][通常論文]
  • Ras-PI3Kシグナルが制御する外来因子取込み機構の解析
    藤岡 容一朗, 津田 真寿美, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 大場 雄介 日本細胞生物学会大会講演要旨集 65回 153 -153 2013年05月 [査読無し][通常論文]
  • 新井 隆太, 渡部 琢哉, 三浪 明男, 津田 真寿美, 大場 雄介 北海道整形災害外科学会 54 (2) 250 2013年03月 [査読無し][通常論文]
  • 川俣太, 本間重紀, 西原広史, 長津明久, 旭火華, 蒲池浩文, 高橋典彦, 津田真寿美, 田中伸哉, 神山俊哉, 武冨紹信 日本消化器癌発生学会総会プログラム・抄録集 24th 85 2013年 [査読無し][通常論文]
  • 川俣太, 本間重紀, 西原広史, 長津明久, 旭火華, 蒲池浩文, 高橋典彦, 津田真寿美, 田中伸哉, 神山俊哉, 武冨紹信 大腸癌研究会プログラム・抄録集 79th 93 2013年 [査読無し][通常論文]
  • 新井 隆太, 渡部 琢哉, 津田 真寿美, 大場 雄介, 三浪 明男 日本整形外科学会雑誌 86 (8) S1101 2012年08月 [査読無し][通常論文]
  • 我妻孝則, 津田真寿美, 山田珠希, 藤岡容一朗, 芳賀永, 戸塚靖則, 進藤正信, 大場雄介 日本分子生物学会年会プログラム・要旨集(Web) 35th 3P-0363 (WEB ONLY) 2012年 [査読無し][通常論文]
  • SrcおよびAuroraキナーゼ2重阻害による滑膜肉腫の相乗的in vivo抗腫瘍効果(Dual inhibition of Src and Aurora kinases abrogates tumor growth, invasion, and angiogenesis of synovial sarcoma in vivo)
    津田 真寿美, 新井 隆太, 渡部 琢哉, 尾瀬 農之, 小布施 力史, 前仲 勝実, 三浪 明男, 大場 雄介 日本癌学会総会記事 70回 274 -274 2011年09月 [査読無し][通常論文]
  • 慢性骨髄白血病に対する分子標的治療薬の反応性・抵抗性判定試験(Seeing response and resistance to BCR-ABL inhibition in chronic myeloid leukemia)
    大場 雄介, 金安 顕子, 水谷 龍明, ダルマニン・ステファニー, 近藤 健, 津田 真寿美 日本癌学会総会記事 70回 242 -242 2011年09月 [査読無し][通常論文]
  • RANKLは口腔癌細胞のインテグリンα2の発現と細胞接着を亢進する(RANKL upregulates integrin α2 expression and cell adhesion in oral cancer cells)
    大場 雄介, 山田 珠希, 藤岡 容一朗, 甲斐原 拓真, 戸塚 泰則, 進藤 正信, 津田 真寿美 日本細胞生物学会大会講演要旨集 63回 156 -156 2011年05月 [査読無し][通常論文]
  • 津田 真寿美, 新井 隆太, 大場 雄介 日本細胞生物学会大会要旨集 63rd 159 2011年05月 [査読無し][通常論文]
  • 染色体・核・遺伝子発現・シグナル伝達 インフルエンザウイルスは、カルシウムシグナル伝達によって、Ras-PI3K-仲介エンドサイトーシスを活性化する(Signal transduction/Chromosome/Cell nucleus/Gene expression Influenza viruses activate Ras-PI3K-mediated endocytosis via calcium signaling)
    藤岡 容一朗, 津田 真寿美, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 宮崎 忠昭, 大場 雄介 日本細胞生物学会大会講演要旨集 63回 112 -112 2011年05月 [査読無し][通常論文]
  • 新井 隆太, 津田 真寿美, 渡部 琢哉, 尾瀬 農之, 小布施 力史, 前仲 勝実, 三浪 明男, 大場 雄介 日本分子生物学会年会プログラム・要旨集(Web) 34th WEB ONLY 2P-0690 2011年 [査読無し][通常論文]
  • RANKL発現は腫瘍形成とEMTを亢進する(RANKL expression promotes tumorigenesis and epithelial mesenchymal transition)
    山田 珠希, 津田 真寿美, 戸塚 靖則, 進藤 正信, 大場 雄介 日本癌学会総会記事 69回 494 -494 2010年08月 [査読無し][通常論文]
  • 新井 隆太, 渡部 琢哉, 津田 真寿美, 川口 秀明, 大場 雄介, 三浪 明男 日本整形外科学会雑誌 84 (8) S1244 2010年08月 [査読無し][通常論文]
  • RANKLは微小環境特異的に発現し細胞接着・EMT・腫瘍形成を促進する生体内特異的機能マーカーである(RANKJL expression specifically observed in vivo promotes cell adhesion, epithelial mesenchymal transition, and tumor progression)
    山田 珠希, 津田 真寿美, 進藤 正信, 戸塚 泰則, 大場 雄介 日本細胞生物学会大会講演要旨集 62回 196 -196 2010年05月 [査読無し][通常論文]
  • メンブレントラフィック Ras-PI3Kシグナル経路がエンドサイトーシスとインフルエンザ感染を調節する(Membrane traffic The Ras-PI3K signaling pathway mediates endocytosis and the incorporation of influenza viruses)
    藤岡 容一朗, 津田 真寿美, 服部 ともえ, 佐々木 純子, 佐々木 雄彦, 宮崎 忠昭, 大場 雄介 日本細胞生物学会大会講演要旨集 62回 117 -117 2010年05月 [査読無し][通常論文]
  • 生体内腫瘍形成における腫瘍微小環境誘発性のRANKL発現の必要性(Requirement for tumor microenvironment-induced RANKL expression in the tumorigenesis in vivo)
    山田 珠希, 津田 真寿美, 戸塚 靖則, 進藤 正信, 大場 雄介 日本癌学会総会記事 68回 47 -47 2009年08月 [査読無し][通常論文]
  • FRETバイオセンサーを用いたCML分子標的薬剤の薬効評価系の構築(A FRET-based biosensor for the evaluation of the efficacy of molecular targeted drugs for chronic myeloid leukemia)
    水谷 龍明, 近藤 健, ダルマニン・ステファニー, 津田 真寿美, 田中 伸哉, 浅香 正博, 大場 雄介 日本癌学会総会記事 68回 457 -457 2009年08月 [査読無し][通常論文]
  • 谷野美智枝, 王磊, 津田真寿美, 西原広史, 大場雄介, 矢野聖二, 曽根三郎, 田中伸哉 日本呼吸器学会雑誌 47 237 2009年05月10日 [査読無し][通常論文]
  • 山田珠希, 津田真寿美, 大場雄介, 川口秀明, 戸塚靖則, 進藤正信 日本病理学会会誌 98 (1) 250 -250 2009年03月20日 [査読無し][通常論文]
  • 水谷龍明, 近藤健, STEPHANIE Darmanin, 津田真寿美, 川口秀明, 浅香正博, 大場雄介 日本病理学会会誌 98 (1) 278 2009年03月20日 [査読無し][通常論文]
  • M. A. Tanino, L. Wang, S. Kohsaka, T. Kimura, K. Sasai, H. Nishihara, M. Tsuda, S. Yano, S. Tanaka AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 179 2009年 [査読無し][通常論文]
  • 新井 隆太, 津田 真寿美, 渡部 琢哉, 川口 秀明, 大場雄介, 三浪 明男 日本分子生物学会年会講演要旨集 32nd (Vol.1) 231 2009年 [査読無し][通常論文]
  • Takayuki Inuzuka, Masumi Tsuda, Shinya Tanaka, Yujiro Higashi, Hideaki Kawaguchi, Yusuke Ohba JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY 45 S11 -S12 2008年10月 [査読無し][通常論文]
  • 山田珠希, 津田真寿美, 大場雄介, 川口秀明, 戸塚靖則, 進藤正信 補体シンポジウム講演集 45th 180 -180 2008年07月 [査読無し][通常論文]
  • 山田珠希, 津田真寿美, 大場雄介, 戸塚靖則, 進藤正信, 川口秀明 適応医学 12 (1) 25 -25 2008年05月20日 [査読無し][通常論文]
  • Kaori Tsutsumi, Masumi Tsuda, Hideaki Kawaguchi, Yusuke Ohba FASEB JOURNAL 22 2008年04月 [査読無し][通常論文]
  • 山田珠希, 津田真寿美, 大場雄介, 川口秀明, 戸塚靖則, 進藤正信 生化学 2P-1143 2008年 [査読無し][通常論文]
  • 水谷龍明, 近藤健, DARMANIN Stephanie, 津田真寿美, 甲斐原拓真, 川口秀明, 浅香正博, 大場雄介 生化学 4P-1171 2008年 [査読無し][通常論文]
  • EGFシグナル伝達はPTHrPの発現を誘導し、口腔癌細胞の悪性化に関与する(EGF signaling regulates PTHrP expression and malignancies in oral cancer cells)
    山田 珠希, 津田 真寿美, 大場 雄介, 戸塚 靖則, 進藤 正信 日本癌学会総会記事 66回 501 -501 2007年08月 [査読無し][通常論文]
  • 水谷龍明, 津田真寿美, 川口秀明, 大場雄介 生化学 4P-0935 2007年 [査読無し][通常論文]
  • 津田真寿美, 田中伸哉, 牧野吉倫, 西原広史, 沢洋文, 長嶋和郎 日本癌学会総会記事 61st 317 2002年08月25日 [査読無し][通常論文]
  • 津田真寿美, 田中伸哉, 西原広史, 沢洋文, 長嶋和郎 日本病理学会会誌 91 (1) 159 2002年02月28日 [査読無し][通常論文]
  • 長井真人, 田中伸哉, 平賀博明, 津田真寿美, 遠藤秀一, 沢洋文, 西原広史, 長嶋和郎 日本病理学会会誌 90 (1) 190 2001年03月01日 [査読無し][通常論文]
  • 長井真人, 田中伸哉, 津田真寿美, 園部宏, 加藤宏幸, 平賀博明, 西原広史, 沢洋文, 長嶋和郎 日本分子生物学会年会プログラム・講演要旨集 23rd 338 2000年11月25日 [査読無し][通常論文]
  • 長井真人, 田中伸哉, 沢洋文, 西原広史, 津田真寿美, 長嶋和郎 Jpn J Cancer Res 91 (Supplement (Sept)) 53 2000年09月01日 [査読無し][通常論文]

講演・口頭発表等

共同研究・競争的資金等の研究課題

  • Crkアダプター分子を用いた幹細胞・EMTヘテロジェナイティーモデルの作製
    文部科学省:科学研究費補助金(挑戦的萌芽研究)
    研究期間 : 2015年 -2016年 
    代表者 : 津田真寿美
  • 文部科学省:科学研究費補助金(基盤研究(C))
    研究期間 : 2012年 -2014年 
    代表者 : 津田 真寿美
  • 文部科学省:科学研究費補助金(挑戦的萌芽研究)
    研究期間 : 2010年 -2011年 
    代表者 : 津田 真寿美
     
    近年増加傾向にある乳癌、前立腺癌、肺癌には、腫瘍発生後比較的早期から骨転移・骨浸潤が高頻度に出現する特徴がある。しかし、この原因は解剖学的位置関係だけでは説明困難であり、なぜこれらの癌が骨転移を起こしやすいのか未だ明らかではない。最近、腫瘍血管内皮細胞が内皮-間葉転換による脱分化の後、骨・軟骨細胞へ再分化して腫瘍組織の石灰化を誘導するという興味深い現象が報告された。これは、血管内皮細胞が作りだした骨類似環境によって、癌細胞が原発巣にいながらにしてすでに高骨親和性を獲得するようにプログラミングされる可能性を示唆している。当研究ではその可能性を検証するため、当該年度はまず、癌細胞と血管内皮細胞のどのような相互作用が腫瘍血管新生を惹起するのか、その詳細な分子メカニズムを解析した。臨床的に高頻度に骨転移を引き起こす滑膜肉腫では、腫瘍細胞がSrcファミリーキナーゼ(SFK)活性依存的に発現分泌するVEGFにより、血管内皮細胞が腫瘍組織へ積極的に導引されることが明らかとなった。SFK阻害剤をマウスの腹腔内へ投与した場合には、腫瘍血管新生が有意に抑制されると同時に、腫瘍の体積及び重量も著明に減少した。一方、高頻度に骨浸潤を引き起こす口腔癌では、癌細胞が分泌する破骨細胞分化因子RANKL依存的に血管内皮細胞が腫瘍組織へ導引されることが明らかとなった。このRANKLの発現はin vitro実験...
  • 文部科学省:科学研究費補助金(基盤研究(B))
    研究期間 : 2008年 -2010年 
    代表者 : 大場 雄介, 津田 真寿美
     
    がん細胞の浸潤・転移や血管内皮細胞の血管新生動員に重要なプロセスである上皮間葉移行(epithelial-mesenchymal transition, EMT)を共通に制御する転写因子TCF8を同定し、TCF8がEMTを制御する分子メカニズムをがん細胞側、血管内皮細胞側のそれぞれで解明した。また、がん間質側の違いが、がんそのものの悪性度に寄与する新たなエビデンスを見出し、新しいがんの制御法につながる新たな知見を提供した。
  • 文部科学省:科学研究費補助金(若手研究(B))
    研究期間 : 2008年 -2009年 
    代表者 : 津田 真寿美
     
    生体内腫瘍環境特異的な癌細胞悪性化因子の解析を進める中で、口腔癌組織特異的に破骨細胞分化因子RANKLが発現誘導されることを同定し、このRANKLが生体内での口腔癌の悪性度を増悪させる重要因子である可能性を見出した。また、高頻度に肺転移を引き起こすヒト滑膜肉腫をモデルにして、腫瘍細胞と血管内皮細胞との相互作用が腫瘍血管新生に極めて重要であること、またSrcファミリー阻害薬がこの血管新生を有効に抑制することを明らかにした。
  • 文部科学省:科学研究費補助金(萌芽研究)
    研究期間 : 2007年 -2008年 
    代表者 : 戸塚 靖則, 津田 真寿美, 進藤 正信, 大場 雄介, 北村 哲也, 樋田 京子, 東野 史裕
     
    口腔がんの多くは舌や歯肉などの口腔内組織に発症するが、これらの臓器・組織は解剖学的に顎骨に近接しており、腫瘍の増大により容易に顎骨に浸潤する。この場合は、腫瘍の根治性の点から、顎骨離断術や部分切断術を施行せざるをえず、顔面の審美性や機能性に多大な障害を生じ、治癒後の社会生活やQOLに大きな影響を及ぼす。それ故、腫瘍の顎骨浸潤を抑制することが可能となれば、口腔がん患者にどって大きな福音となり、その開発が真に望まれている。口腔癌細胞の多くは、epidemal growth factor (EGF) receptorを高頻度に発現しており、また顎下腺並びに唾液中には高濃度のEGFが存在していることが明らかになっている。従って、口腔癌の微小環境中に存在するEGFが、癌細胞に対してパラクライン的に作用し、骨浸潤に関与する形質発現に重要な影響を及ぼしていることが示唆される。口腔がん細胞株HSC2, HSC3, HSC4, Ca9.22, SASを用いてEGFRの発現をWestern Blotで検討したところ、全てのがん細胞株でEGFRの発現亢進がみられた。これらの細胞をEGFで刺激した際、EGFRのリン酸化の亢進およびMAPKであるERK1/2, p38.JNKの活性化がみられた。ERK1/2はEGF依存的にPTHrPを発現亢進した。HSC2細胞にPTHrPのsiRNAを導入することで細...
  • 文部科学省:科学研究費補助金(特別研究促進費, 若手研究(B))
    研究期間 : 2006年 -2007年 
    代表者 : 津田 真寿美
     
    染色体転座に由来する悪性腫瘍の多くは複雑な細胞動態を示し、一般的な化学療法に耐性で予後も悪いことから、より効果的な抗がん剤の適用やその診断が急務の課題となっている。我々は、平成18年度の研究より、キメラ遺伝子産物SYT-SSXを発現するヒト滑膜肉腫において、ある種のチロシンキナーゼ阻害剤がその増殖能や細胞運動能を著明に低下させることを明らかにした(特許出願:2007-3808)。この成果に基づき、当該年度においては、in vivoマウスにおけるチロシンキナーゼ阻害剤の抗腫瘍効果を検討した。ヌードマウスの皮下にヒト滑膜肉腫細胞株を接種して腫瘍塊を形成後、チロシンキナーゼ阻害剤を腹腔内投与し、腫瘍内のシグナル伝達抑制効果を経時的に解析した。この薬剤投与により、シグナル伝達経路のスウィチング分子として機能するGabl、さらには滑膜肉腫の増殖能に関与するp38 MAPKのリン酸化が著明に抑制されることが明らかとなった。この結果は、in vitroでの我々の解析結果と一致した。現在、この薬剤によるin vivoでの腫瘍抑制効果について更に検討中であり、臨床治験への可能性に向けて米国創薬会社と議論中である。更に、我々は染色体転座に由来する血液疾患である慢性骨髄性白血病(Chronic myelogenous leukemia;CML)において、蛍光共鳴エネルギー移動(Fluorescen...

産業財産権



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.